{"content":"<li class=\"n-box-item date-title\" data-end=\"1563854399\" data-start=\"1563768000\" data-txt=\"Monday, December 23, 2019\">Monday, July 22, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3479962\" data-ts=\"1563836372\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479962-synopsys-slips-following-guidance-from-rival-cadence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synopsys slips following guidance from rival Cadence</a></h4><ul>   <li>Synopsys (NASDAQ:<a href='https://seekingalpha.com/symbol/SNPS' title='Synopsys, Inc.'>SNPS</a>) is <font color=\"red\">off 7.7%</font> after hours following an <a href=\"https://seekingalpha.com/news/3479868-cadence-design-minus-5-percent-line-outlook\" target=\"_blank\">earnings report</a> from rival Cadence Design Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CDNS' title='Cadence Design Systems, Inc.'>CDNS</a>) that featured guidance that slightly trailed consensus at the midpoint.</li>    <li>That's now bigger than Cadence's own postmarket drop; Cadence had fallen as low as $65.81 but is back to a <font color=\"red\">1.6% decline</font> at $71.50 in after-hours quotes.</li>    <li>The guidance could have prompted worries about a hot sector. Synopsys is <font color=\"green\">up 60.8%</font> YTD, with <font color=\"green\">15.8% gains</font> coming over the past quarter.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479962\" data-linked=\"Synopsys slips following guidance from rival Cadence\" data-tweet=\"$SNPS $CDNS - Synopsys slips following guidance from rival Cadence https://seekingalpha.com/news/3479962-synopsys-slips-following-guidance-from-rival-cadence?source=tweet\" data-url=\"https://seekingalpha.com/news/3479962-synopsys-slips-following-guidance-from-rival-cadence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479954\" data-ts=\"1563834446\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479954-snapplus-1_8-stifel-upgrades-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap +1.8% as Stifel upgrades to Buy</a></h4><ul>   <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) shares are <font color=\"green\">up 1.8%</font> after hours following an upgrade to Buy at Stifel, from Hold.</li>    <li>The firm raised its price target to $17 from $13, implying 20% upside from today's close.</li>    <li>Sentiment is otherwise quite Neutral across the board: Sell-side analysts rate Snap a <a href=\"https://seekingalpha.com/symbol/SNAP/ratings/sell-side-ratings\" target=\"_blank\">Hold on average</a>, <a href=\"https://seekingalpha.com/symbol/SNAP/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Neutral</a>, and the stock has a <a href=\"https://seekingalpha.com/symbol/SNAP/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479954\" data-linked=\"Snap +1.8% as Stifel upgrades to Buy\" data-tweet=\"$SNAP - Snap +1.8% as Stifel upgrades to Buy https://seekingalpha.com/news/3479954-snapplus-1_8-stifel-upgrades-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3479954-snapplus-1_8-stifel-upgrades-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479945\" data-ts=\"1563832877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVCO\" target=\"_blank\">AVCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479945-avalon-globocareplus-22-on-partnership-ge-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avalon GloboCare +22% on partnership with GE Healthcare</a></h4><ul>   <li>Avalon GloboCare (NASDAQ:<a href='https://seekingalpha.com/symbol/AVCO' title='Avalon GloboCare Corp.'>AVCO</a>) is <font color=\"green\">up 22%</font> postmarket after announcing a <a href=\"https://seekingalpha.com/pr/17578710-avalon-globocare-ge-healthcare-announce-strategic-partnership-accelerate-standardized\" target=\"_blank\">strategic partnership</a> with GE Healthcare on cellular medicines.</li>    <li>The team-up will accelerate standardization, automation and bio-production for clinical-grade CAR-T cells and other immune-effector cells for cellular immunotherapy, as well as EV-based regenerative therapeutics.</li>    <li>Both companies will establish automated and standardized GMP cell production capability, and Avalon will get access to GE Healthcare's cell processing expertise and products in the form of the FlexFactory Cell Therapy platform.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479945\" data-linked=\"Avalon GloboCare +22% on partnership with GE Healthcare\" data-tweet=\"$AVCO - Avalon GloboCare +22% on partnership with GE Healthcare https://seekingalpha.com/news/3479945-avalon-globocareplus-22-on-partnership-ge-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3479945-avalon-globocareplus-22-on-partnership-ge-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479935\" data-ts=\"1563831338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479935-acad-phm-lci-and-cdns-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ACAD, PHM, LCI and CDNS among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/PRCP' title='Perceptron, Inc.'>PRCP</a> <font color=\"green\">+12.2%</font>. <a href='https://seekingalpha.com/symbol/PHM' title='PulteGroup, Inc.'>PHM</a> <font color=\"green\">+1.8%</font>. <a href='https://seekingalpha.com/symbol/AVRO' title='AVROBIO, Inc.'>AVRO</a> <font color=\"green\">+1.5%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/ACAD' title='ACADIA Pharmaceuticals Inc.'>ACAD</a> <font color=\"red\">-11.7%</font>.<strong> </strong><a href='https://seekingalpha.com/symbol/ZION' title='Zions Bancorporation, National Association'>ZION</a> <font color=\"red\">-4.4%</font>. <a href='https://seekingalpha.com/symbol/CDNS' title='Cadence Design Systems, Inc.'>CDNS</a> <font color=\"red\">-3.3%</font>.<a href='https://seekingalpha.com/symbol/UGP' title='Ultrapar Participações S.A.'>UGP</a> <font color=\"red\">-3.2%</font>. <a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc.'>LCI</a> <font color=\"red\">-3.2%. </font></li></ul><div class=\"tiny-share-widget\" data-id=\"3479935\" data-linked=\"ACAD, PHM, LCI and CDNS among after hour movers\" data-tweet=\"$PRCP $PHM $AVRO - ACAD, PHM, LCI and CDNS among after hour movers https://seekingalpha.com/news/3479935-acad-phm-lci-and-cdns-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3479935-acad-phm-lci-and-cdns-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479929\" data-ts=\"1563830856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479929-apple-intel-in-advanced-talks-over-modem-business-wsj\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple, Intel in advanced talks over modem business - WSJ</a></h4><ul>   <li>Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) is in <a href=\"https://www.wsj.com/articles/apple-in-advanced-talks-to-buy-intels-smartphone-modem-chip-business-11563830356?mod=e2tw\" target=\"_blank\">advanced talks</a> to buy Intel's (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) smartphone modem-chip business, the Wall Street Journal reports, another step in what could be a major push for internal modem development.</li>    <li>A deal could value a portfolio of patents and staff at $1B or more and could come in the next week, according to the report.</li>    <li>Earlier talks were <a href=\"https://seekingalpha.com/news/3470623-apple-talks-buy-key-intel-modem-unit-report\" target=\"_blank\">reported in June</a>, showing some momentum there.</li>    <li>Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='QUALCOMM Incorporated'>QCOM</a>) dipped on that June report, and is <font color=\"red\">3% lower</font> after hours today. Previous talks between Apple and Intel had broken down around the time Apple struck a multiyear supply deal with Qualcomm.</li>    <li>Intel is <font color=\"green\">up 2%</font> after hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479929\" data-linked=\"Apple, Intel in advanced talks over modem business - WSJ\" data-tweet=\"$AAPL $INTC $QCOM - Apple, Intel in advanced talks over modem business - WSJ https://seekingalpha.com/news/3479929-apple-intel-in-advanced-talks-over-modem-business-wsj?source=tweet\" data-url=\"https://seekingalpha.com/news/3479929-apple-intel-in-advanced-talks-over-modem-business-wsj\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>110&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479908\" data-ts=\"1563828611\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZION\" target=\"_blank\">ZION</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479908-zionsminus-4_4-q2-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zions -4.4% as Q2 disappoints</a></h4><ul><li>Zions Bancorporation (NASDAQ:<a href='https://seekingalpha.com/symbol/ZION' title='Zions Bancorporation, National Association'>ZION</a>) <font color=\"red\">slumps 4.7%</font> in after-hours trading after<a href=\"https://seekingalpha.com/pr/17578630-zions-bancorporation-national-association-reports-second-quarter-financial-results\" target=\"_blank\"> Q2 EPS</a> of 99 cents missed the average analyst estimate of $1.10.</li><li>Fell from Q1 EPS of $1.04 and increased from 89 cents a year ago; net income of $189M slipped from $205M in Q1 and rose slightly from $187M a year ago.</li><li>Reflects \"relatively strong loan growth coupled with margin compression resulting from a challenging interest rate environment,\" said Chairman and CEO Harris H. Simmons.</li><li>Q2 EPS rose 11% as share count was 9% lower.</li><li>Net interest income of $569M rose 4% Y/Y; net interest margin was 3.54% vs. 3.56%.</li><li>Net loans and leases of $48.6B rose 7% Y/Y.</li><li>Provision for credit losses were $21M vs. $12M in the year-ago period.</li><li>Return on average tangible common equity increased to 12.7% from 12.4% a year earlier.</li><li><a href=\"https://edge.media-server.com/mmc/p/wsoa69pz\" target=\"_blank\">Conference call</a> at 5:30 PM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3479872-zions-eps-misses-0_11-misses-revenue\" target=\"_blank\">Zions EPS misses by $0.11, misses on revenue</a> (July 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3479908\" data-linked=\"Zions -4.4% as Q2 disappoints\" data-tweet=\"$ZION - Zions -4.4% as Q2 disappoints https://seekingalpha.com/news/3479908-zionsminus-4_4-q2-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3479908-zionsminus-4_4-q2-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479905\" data-ts=\"1563828156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRCP\" target=\"_blank\">PRCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479905-perceptronplus-17_5-on-robot-guidance-orders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Perceptron +17.5% on robot guidance orders</a></h4><ul><li>Perceptron (NASDAQ:<a href='https://seekingalpha.com/symbol/PRCP' title='Perceptron, Inc.'>PRCP</a>) <a href=\"https://seekingalpha.com/pr/17578639-perceptron-announces-robot-guidance-orders-electric-vehicle-production\" target=\"_blank\">announces</a> receiving two robot guidance orders involving battery packs. No financial terms were disclosed.</li><li>The orders came from two different OEM partners.</li><li>The first project is currently being installed and the second is scheduled for this fall.</li><li>PRCP shares are up <font color=\"green\">17.5%</font> after hours to $4.26.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479905\" data-linked=\"Perceptron +17.5% on robot guidance orders\" data-tweet=\"$PRCP - Perceptron +17.5% on robot guidance orders https://seekingalpha.com/news/3479905-perceptronplus-17_5-on-robot-guidance-orders?source=tweet\" data-url=\"https://seekingalpha.com/news/3479905-perceptronplus-17_5-on-robot-guidance-orders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479882\" data-ts=\"1563827247\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACAD\" target=\"_blank\">ACAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479882-acadia-pharmas-pimavanserin-flunks-late-stage-schizophrenia-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acadia Pharma&#39;s pimavanserin flunks late-stage schizophrenia study</a></h4><ul><li>ACADIA Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACAD' title='ACADIA Pharmaceuticals Inc.'>ACAD</a>) is poised for a down move in response to its <a href=\"https://seekingalpha.com/pr/17578604-acadia-pharmaceuticals-announces-top-line-results-phase-3-enhance-trial-pimavanserin\" target=\"_blank\">announcement </a>that adding lead drug pimavanserin to existing antipsychotic therapy in schizophrenia patients failed to demonstrate enough of a treatment effect compared to placebo in a Phase 3 study called <a href=\"https://clinicaltrials.gov/ct2/show/NCT02970292?lead=acadia+pharmaceuticals&amp;phase=2&amp;rank=8\" target=\"_blank\">ENHANCE</a>.</li><li>Specifically, a measure of psychotic symptoms, a scale called PANSS, showed a \"consistent trend in improvement\" in the pimavanserin + current therapy cohort, but the separation from the placebo + existing therapy group fell short of statistical significance (p=0.0940).</li><li>Results from a subgroup of European patients were statistically valid as were measures of negative symptoms.</li><li>A Phase 2 trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02970305?lead=acadia+pharmaceuticals&amp;phase=12&amp;rank=12\" target=\"_blank\">ADVANCE</a>, in schizophrenia patients with predominantly negative symptoms should be completed shortly.</li><li>Management will host a conference call today at 5:00 pm ET to discuss the Phase 3 data.</li><li><strong>Update</strong>: Shares are down <font color=\"red\">12%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479882\" data-linked=\"Acadia Pharma&#39;s pimavanserin flunks late-stage schizophrenia study\" data-tweet=\"$ACAD - Acadia Pharma&#39;s pimavanserin flunks late-stage schizophrenia study https://seekingalpha.com/news/3479882-acadia-pharmas-pimavanserin-flunks-late-stage-schizophrenia-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3479882-acadia-pharmas-pimavanserin-flunks-late-stage-schizophrenia-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479868\" data-ts=\"1563826775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479868-cadence-designminus-5-after-in-line-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cadence Design -5% after in-line outlook</a></h4><ul><li>Cadence Design Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CDNS' title='Cadence Design Systems, Inc.'>CDNS</a>) <font color=\"red\">-5%</font> <a href=\"https://seekingalpha.com/news/3479848-cadence-design-systems-eps-beats-0_04-beats-revenue\" target=\"_blank\">reports Q2 beats</a> with in-line Q3 guidance that has revenue of $570-580M (consensus: $576.12M) and EPS of $0.50-0.52 (consensus: $0.50).</li><li>The FY19 outlook has in-line revenue of $2.315-2.335B (consensus: $2.32B) and upside EPS of $2.11 to $2.17 (consensus: $2.09).</li><li>The Q2 non-GAAP operating margin was 34% versus last year's 30%.</li><li>Earnings call starts at 5 PM ET with a webcast <a href=\"https://www.cadence.com/content/cadence-www/global/en_US/home/company/investors.html\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17578610-cadence-reports-second-quarter-2019-financial-results\" target=\"_blank\">Press release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3479868\" data-linked=\"Cadence Design -5% after in-line outlook\" data-tweet=\"$CDNS - Cadence Design -5% after in-line outlook https://seekingalpha.com/news/3479868-cadence-designminus-5-after-in-line-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3479868-cadence-designminus-5-after-in-line-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479864\" data-ts=\"1563826683\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WHR\" target=\"_blank\">WHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479864-whirlpoolplus-5-after-profit-beat-strong-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Whirlpool +5% after profit beat, strong guidance</a></h4><ul><li>Whirlpool (NYSE:<a href='https://seekingalpha.com/symbol/WHR' title='Whirlpool Corporation'>WHR</a>) trades higher after topping Q2 profit estimates and setting stronger-than-anticipated EPS guidance despite some macro headwinds.</li><li>The company anticipates full-year EPS of $14.75 to $15.50 vs $14.78 consensus. Whirlpool also expects to generate cash provided by operating activities of ~$1.4B and free cash flow of approximately ~$800M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3479856-whirlpool-eps-beats-0_29-beats-revenue\" target=\"_blank\">Whirlpool EPS beats by $0.29, beats on revenue</a> (July 22)</li><li>Whirlpool <font color=\"green\">+ 5.0%</font> AH.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479864\" data-linked=\"Whirlpool +5% after profit beat, strong guidance\" data-tweet=\"$WHR - Whirlpool +5% after profit beat, strong guidance https://seekingalpha.com/news/3479864-whirlpoolplus-5-after-profit-beat-strong-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3479864-whirlpoolplus-5-after-profit-beat-strong-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479856\" data-ts=\"1563826359\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WHR\" target=\"_blank\">WHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479856-whirlpool-eps-beats-0_29-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Whirlpool EPS beats by $0.29, beats on revenue</a></h4><ul><li>Whirlpool (NYSE:<a href='https://seekingalpha.com/symbol/WHR' title='Whirlpool Corporation'>WHR</a>): Q2 Non-GAAP EPS of $4.01 <font color=\"green\">beats by $0.29</font>; GAAP EPS of $1.04 <font color=\"red\">misses by $2.45</font>.</li><li>Revenue of $5.19B (+1.0% Y/Y) <font color=\"green\">beats by $160M</font>.</li><li>Shares <font color=\"green\">+5.6%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17578633-whirlpool-corporation-reports-strong-second-quarter-2019-results-raises-full-year-guidance\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3479856\" data-linked=\"Whirlpool EPS beats by $0.29, beats on revenue\" data-tweet=\"$WHR - Whirlpool EPS beats by $0.29, beats on revenue https://seekingalpha.com/news/3479856-whirlpool-eps-beats-0_29-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3479856-whirlpool-eps-beats-0_29-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479851\" data-ts=\"1563826099\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MT\" target=\"_blank\">MT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479851-arcelormittal-again-hikes-u-s-flat-rolled-steel-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArcelorMittal again hikes U.S. flat-rolled steel prices</a></h4><ul><li>ArcelorMittal (<a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color=\"green\">+2.6%</font>) says it is <a href=\"https://www.spglobal.com/platts/en/market-insights/latest-news/metals/072219-arcelormittal-usa-kicks-off-a-third-round-of-sheet-price-increases\" target=\"_blank\">raising flat-rolled steel prices</a> for its U.S. customers, marking the third round of increases  since the end of June.</li><li>MT's U.S. subsidiary will charge new minimum base prices of $630/st for hot-rolled coil  and $800/st for cold-rolled and coated coil products, effective immediately.</li><li>MT's new numbers are up $30-$70/st from existing HRC offers in the market, according to S&amp;P Global Platts.</li><li>The two previous rounds of increases have been effective in raising spot prices but mills have fallen short of collecting the full amount, S&amp;P Global says.</li><li>ETF: <a href='https://seekingalpha.com/symbol/SLX' title='VanEck Vectors Steel ETF'>SLX</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3479851\" data-linked=\"ArcelorMittal again hikes U.S. flat-rolled steel prices\" data-tweet=\"$MT $SLX - ArcelorMittal again hikes U.S. flat-rolled steel prices https://seekingalpha.com/news/3479851-arcelormittal-again-hikes-u-s-flat-rolled-steel-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3479851-arcelormittal-again-hikes-u-s-flat-rolled-steel-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479841\" data-ts=\"1563825791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMTD\" target=\"_blank\">AMTD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479841-td-ameritrade-eps-beats-0_07-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TD Ameritrade EPS beats by $0.07, beats on revenue</a></h4><ul><li>TD Ameritrade (NASDAQ:<a href='https://seekingalpha.com/symbol/AMTD' title='TD Ameritrade Holding Corporation'>AMTD</a>): Q2 Non-GAAP EPS of $1.04 <font color=\"green\">beats by $0.07</font>; GAAP EPS of $1.00 <font color=\"green\">beats by $0.08</font>.</li><li>Revenue of $1.49B (+8.0% Y/Y) <font color=\"green\">beats by $20M</font>.</li><li>Shares <font color=\"green\">+1.2%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17578579-td-ameritrade-reports-third-quarter-fiscal-2019-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3479841\" data-linked=\"TD Ameritrade EPS beats by $0.07, beats on revenue\" data-tweet=\"$AMTD - TD Ameritrade EPS beats by $0.07, beats on revenue https://seekingalpha.com/news/3479841-td-ameritrade-eps-beats-0_07-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3479841-td-ameritrade-eps-beats-0_07-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479836\" data-ts=\"1563825295\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEOH\" target=\"_blank\">MEOH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479836-methanex-price-target-trimmed-rbc-after-geismar-project-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Methanex price target trimmed at RBC after Geismar project news</a></h4><ul><li>Methanex (<a href='https://seekingalpha.com/symbol/MEOH' title='Methanex Corporation'>MEOH</a> <font color='red'>-6.4%</font>) sinks to a 52-week low following <a href=\"https://seekingalpha.com/news/3479459-methanex-move-ahead-geismar-3-project\" target=\"_blank\">Friday's announcement</a> that it will build a 1.8M-ton methanol plant adjacent to its Geismar 1 and 2 facilities in Louisiana, likely costing $1.3B-$1.4B.</li><li>Citing \"weak economic sentiment,\" RBC Capital analyst Nelson Ng <a href=\"https://thefly.com/thestreet/realmoney/index.php/MEOHid2935922/MEOH-Methanex-price-target-lowered-to--from--at-RBC-Capital\" target=\"_blank\">trims his stock price target</a> to $65 from $70 while reiterating his Sector Perform rating and cuts his FY 2020 expected adjusted EBITDA to $858M from $933M to reflect IHS's updated methanol price forecast.</li><li>Ng also says MEOH's decision to move ahead with Geismar 3 development is not surprising given its history of a \"balanced approach to capital allocation\" but says in spite of the project's attractive economics, he prefers to await more visibility in the market.</li><li>MEOH's average <a href=\"https://seekingalpha.com/symbol/MEOH/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Hold, while its <a href=\"https://seekingalpha.com/symbol/MEOH/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Very Bearish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479836\" data-linked=\"Methanex price target trimmed at RBC after Geismar project news\" data-tweet=\"$MEOH - Methanex price target trimmed at RBC after Geismar project news https://seekingalpha.com/news/3479836-methanex-price-target-trimmed-rbc-after-geismar-project-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3479836-methanex-price-target-trimmed-rbc-after-geismar-project-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479831\" data-ts=\"1563823425\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UA\" target=\"_blank\">UA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479831-look-for-roe-growth-when-market-treads-water-goldman-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Look for ROE growth when market treads water, Goldman says.</a></h4><ul><li>After the S&amp;P 500's almost 19% gain YTD, the<a href=\"https://www.cnbc.com/2019/07/22/goldman-sachs-the-market-is-stuck-so-buy-these-companies-that-can-grow-earnings-instead.html?__source=twitter%7Cmain\" target=\"_blank\"> index is now trading near </a>its fair value relative to interest rates, profitability, and price-to-book valuations, writes Goldman Sach chief U.S. strategist, David Kostin.</li><li>\u201cWe believe policy uncertainty and negative revisions to 2020 EPS forecasts will limit equity upside,\" he writes in a note.</li><li>Lower interest rates and lower tax rates may provide some support, he acknowledges.</li><li>In an environment of slower economic growth, Goldman is advising its clients to look for stocks with the best expected return-on-equity growth.</li><li>Goldman's basket of 50 S&amp;P 500 stocks with the highest consensus estimates of ROE growth has outperformed the S&amp;P 500 by 5 percentage points YTD.</li><li>Among the stocks in that basket are Under Armour (<a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc.'>UA</a> <font color='red'>-1.5%</font>), Apple (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+2%</font>), Cisco (<a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a> <font color='green'>+0.8%</font>), Sempra Energy (<a href='https://seekingalpha.com/symbol/SRE' title='Sempra Energy'>SRE</a> <font color='green'>+0.6%</font>), and Global Payments (<a href='https://seekingalpha.com/symbol/GPN' title='Global Payments Inc.'>GPN</a> <font color='red'>-0.4%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3479831\" data-linked=\"Look for ROE growth when market treads water, Goldman says.\" data-tweet=\"$UA $AAPL $CSCO - Look for ROE growth when market treads water, Goldman says. https://seekingalpha.com/news/3479831-look-for-roe-growth-when-market-treads-water-goldman-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3479831-look-for-roe-growth-when-market-treads-water-goldman-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479830\" data-ts=\"1563822932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYB\" target=\"_blank\">LYB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479830-chemical-stocks-lyondell-westlake-pummeled-amid-nomura-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chemical stocks Lyondell, Westlake pummeled amid Nomura downgrade</a></h4><ul><li>Lyondell Basell (<a href='https://seekingalpha.com/symbol/LYB' title='LyondellBasell Industries N.V.'>LYB</a> <font color=\"red\">-2%</font>) and Westlake Chemical (<a href='https://seekingalpha.com/symbol/WLK' title='Westlake Chemical Corporation'>WLK</a> <font color=\"red\">-1.5%</font>) are lower after Nomura <a href=\"https://www.barrons.com/articles/sell-chemical-stocks-but-not-because-of-the-economy-or-plastic-bans-51563810166\" target=\"_blank\">downgrades</a> both companies, as analyst Aleksey Yefremov foresees too much plastic-making capacity coming online in the southern U.S.</li><li>Yefremov says U.S.-based ethylene and polyethylene producers \"got lucky\" in H1 2019 because large  U.S. capacity additions were delayed until H2, but despite a healthy Q2,  the outlook for the next 6-9 months is \"increasingly  challenging,\" as the analyst sees 2.4M tons of capacity coming on  line over the next six months, amounting to 12% of U.S. polyethylene  capacity and 2% of global capacity.</li><li>Yefremov thinks these trends warrant near-term caution on producers LYB, which he downgrades to Neutral from Buy with a $93 price target, lowered from $107, and WLK, cut to Reduce from Neutral with a $57 target, trimmed from $58.</li><li>WLK makes caustic soda as well as polyethylene-derived products, and Yefremov says his \"main concern remains excessive investor expectations for recovery in caustic soda market.\"</li><li>However, he maintains a Buy rating on Dow Inc. (<a href='https://seekingalpha.com/symbol/DOW' title='Dow Inc.'>DOW</a> <font color=\"red\">-1.1%</font>), citing better prospects in its non-polyethylene portfolio.</li><li>LYB's average <a href=\"https://seekingalpha.com/symbol/LYB/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform and its <a href=\"https://seekingalpha.com/symbol/LYB/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> is Bullish, while its <a href=\"https://seekingalpha.com/symbol/LYB/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li><li>WLK's <a href=\"https://seekingalpha.com/symbol/WLK/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform and its <a href=\"https://seekingalpha.com/symbol/WLK/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Bearish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479830\" data-linked=\"Chemical stocks Lyondell, Westlake pummeled amid Nomura downgrade\" data-tweet=\"$LYB $WLK $DOW - Chemical stocks Lyondell, Westlake pummeled amid Nomura downgrade https://seekingalpha.com/news/3479830-chemical-stocks-lyondell-westlake-pummeled-amid-nomura-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3479830-chemical-stocks-lyondell-westlake-pummeled-amid-nomura-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479827\" data-ts=\"1563822059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479827-microcaps-top-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps top tech movers</a></h4><ul><li><strong>Gainers: </strong>Atomera Incorporated (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOM' title='Atomera Incorporated'>ATOM</a>) <font color=\"green\">+14%</font>. Verb Technology Company (NASDAQ:<a href='https://seekingalpha.com/symbol/VERB' title='Verb Technology Company, Inc.'>VERB</a>) <font color=\"green\">+8%</font>. Perion Network (NASDAQ:<a href='https://seekingalpha.com/symbol/PERI' title='Perion Network Ltd.'>PERI</a>) <font color=\"green\">+7%</font>. Ideanomics (NASDAQ:<a href='https://seekingalpha.com/symbol/IDEX' title='Ideanomics, Inc.'>IDEX</a>) <font color=\"green\">+7%</font>. Technical Communications Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corporation'>TCCO</a>) <font color=\"green\">+7%</font>.</li> <li><strong>Losers: </strong>Vislink Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/VISL' title='Vislink Technologies, Inc.'>VISL</a>) <font color=\"red\">-12%</font>. Tufin Software Technologies (NYSE:<a href='https://seekingalpha.com/symbol/TUFN' title='Tufin Software Technologies Ltd.'>TUFN</a>) <font color=\"red\">-12%</font>. Sphere 3D (NASDAQ:<a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a>) <font color=\"red\">-11%</font>. Dolphin Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/DLPN' title='Dolphin Entertainment, Inc.'>DLPN</a>) <font color=\"red\">-10%</font>. Identiv (NASDAQ:<a href='https://seekingalpha.com/symbol/INVE' title='Identiv, Inc.'>INVE</a>) <font color=\"red\">-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479827\" data-linked=\"Microcaps top tech movers\" data-tweet=\"$ATOM $VERB $PERI - Microcaps top tech movers https://seekingalpha.com/news/3479827-microcaps-top-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3479827-microcaps-top-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479824\" data-ts=\"1563821451\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CQP\" target=\"_blank\">CQP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479824-blackstone-weighs-cheniere-energy-partners-stake-sale-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blackstone weighs Cheniere Energy Partners stake sale - Bloomberg</a></h4><ul><li>Cheniere Energy Partners (<a href='https://seekingalpha.com/symbol/CQP' title='Cheniere Energy Partners, L.P.'>CQP</a> <font color='green'>+1.8%</font>) is higher after Bloomberg reports Blackstone (<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group Inc.'>BX</a> <font color='green'>+4.9%</font>) is working with an advisor on a <a href=\"https://finance.yahoo.com/news/blackstone-weighs-cheniere-energy-partners-170917114.html\" target=\"_blank\">potential sale of its interest</a> in the partnership.</li><li>BX - which owned 203.4M common units in CQP as of Feb. 20, worth $8.8B based on its unit price as of mid-day Monday - is seeking a premium for its stake and marketing it to a small number of infrastructure, pension and sovereign wealth funds, according to the report.</li><li>BX agreed to invest ~$1.5B in CQP in 2012, when the company was set up by Cheniere Energy (<a href='https://seekingalpha.com/symbol/LNG' title='Cheniere Energy, Inc.'>LNG</a> <font color='green'>+0.9%</font>) to house Louisiana's Sabine Pass, the first major terminal in the lower 48 states to export shale gas overseas; since then, three other projects have begun producing LNG, with two more scheduled to start up soon and several others planned or proposed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479824\" data-linked=\"Blackstone weighs Cheniere Energy Partners stake sale - Bloomberg\" data-tweet=\"$CQP $BX $LNG - Blackstone weighs Cheniere Energy Partners stake sale - Bloomberg https://seekingalpha.com/news/3479824-blackstone-weighs-cheniere-energy-partners-stake-sale-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3479824-blackstone-weighs-cheniere-energy-partners-stake-sale-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479822\" data-ts=\"1563821183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479822-semis-gain-on-goldman-optimism-earnings-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semis gain on Goldman optimism, earnings ahead</a></h4><ul><li>The Philadelphia Semiconductor Index is <font color=\"green\">up 1.8%</font> compared to the tech sector's (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>) <font color=\"green\">1.1%</font> gain after this morning's <a href=\"https://seekingalpha.com/news/3479552-goldman-turns-bullish-semi-equipment\" target=\"_blank\">Goldman Sachs note</a> upgrading several semi equipment names on early signs of memory stabilization.</li><li>Semi names reporting earnings this week: Texas Instruments and Teradyne after hours on Tuesday; Silicon Labs pre-market and plus Mellanox and Xilinx after hours on Wednesday; and STMicroelectronics pre-market and Intel post-market on Thursday.</li><li>Related semiconductor ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3479822\" data-linked=\"Semis gain on Goldman optimism, earnings ahead\" data-tweet=\"$XLK $SOXL $SOXX - Semis gain on Goldman optimism, earnings ahead https://seekingalpha.com/news/3479822-semis-gain-on-goldman-optimism-earnings-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3479822-semis-gain-on-goldman-optimism-earnings-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479821\" data-ts=\"1563821174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEB\" target=\"_blank\">HEB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479821-hemispherx-down-21-on-stock-sales-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hemispherx down 21% on stock sales deal</a></h4><ul><li>Thinly traded nano cap Hemispherx Biopharma (<a href='https://seekingalpha.com/symbol/HEB' title='Hemispherx Biopharma, Inc.'>HEB</a> <font color=\"red\">-20.5%</font>) is down on 40% higher volume, albeit on turnover of only 272K shares, in apparent response to its <a href=\"https://www.sec.gov/Archives/edgar/data/946644/000149315219010927/form424b5.htm\" target=\"_blank\">agreement </a>with Maxim Group to sell up to ~$4.5M of its common stock at market prices.</li><li>Maxim will earn a 3.5% commission for its efforts.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479821\" data-linked=\"Hemispherx down 21% on stock sales deal\" data-tweet=\"$HEB $AIM - Hemispherx down 21% on stock sales deal https://seekingalpha.com/news/3479821-hemispherx-down-21-on-stock-sales-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3479821-hemispherx-down-21-on-stock-sales-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479820\" data-ts=\"1563820936\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479820-new-age-beveragesminus-7-after-northland-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages -7% after Northland cut</a></h4><ul><li>New Age Beverages (<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-7.2%</font>) slumps after Northland Capital Markets downgrades the beverage stock to Market perform from Outperform on its forecast for slower revenue growth.</li><li>Northland also cut its price target on NBEV to $5 from $8 vs. the <a href=\"https://seekingalpha.com/symbol/NBEV/ratings/sell-side-ratings\" target=\"_blank\">sell-side average PT</a> of $9.00.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479820\" data-linked=\"New Age Beverages -7% after Northland cut\" data-tweet=\"$NBEV - New Age Beverages -7% after Northland cut https://seekingalpha.com/news/3479820-new-age-beveragesminus-7-after-northland-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3479820-new-age-beveragesminus-7-after-northland-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479819\" data-ts=\"1563820562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479819-ge-benefit-from-737-max-grounding-bearish-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE could benefit from 737 MAX grounding, bearish analyst says</a></h4><ul><li>Boeing's delays will be <a href=\"https://www.barrons.com/articles/ge-stock-earnings-report-benefit-from-boeing-737-max-grounding-51563808312\" target=\"_blank\">free cash flow positive</a> for General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric Company'>GE</a> <font color='green'>+1.8%</font>) this  quarter, says J.P. Morgan's longtime GE bear Stephen Tusa, adding the company is \"<a href=\"https://www.cnbc.com/2019/07/22/general-electric-tusa-says-expect-more-of-the-same-from-troubled-ge.html\" target=\"_blank\">set up to beat</a>\" Wall Street consensus on the closely watched metric.</li><li>Q2 \"will have an unusually low amount of loss leading  equipment deliveries as the [737 MAX LEAP engines are] grounded with the  MAX, with production likely shifting to highly profitable spare engine  sales,\" Tusa writes, adding fewer new deliveries in GE Power could have the same impact as fewer new LEAP  engines for GE cash flow - a skewing to higher-margin parts and service  revenues.</li><li>Tusa sees cash burn of ~$700M in Q2, vs. company guidance of $1B-$2B.</li><li>Even so, Tusa remains bearish on the stock and believes Q4 will be GE's toughest quarter this year  because of \"seasonal factors and higher spending to restructure GE  business units,\" seeing \"the same dynamic here where despite a 4Q18 'beat' on FCF, the forward FCF estimate has been cut by ~30%.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3479819\" data-linked=\"GE could benefit from 737 MAX grounding, bearish analyst says\" data-tweet=\"$GE - GE could benefit from 737 MAX grounding, bearish analyst says https://seekingalpha.com/news/3479819-ge-benefit-from-737-max-grounding-bearish-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3479819-ge-benefit-from-737-max-grounding-bearish-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>81&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479818\" data-ts=\"1563819646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAL\" target=\"_blank\">HAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479818-halliburtonplus-8-after-idling-fracking-gear-cutting-costs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Halliburton +8% after idling fracking gear, cutting costs</a></h4><ul><li>Halliburton (<a href='https://seekingalpha.com/symbol/HAL' title='Halliburton Company'>HAL</a> <font color='green'>+8.1%</font>), the worst performer in the S&amp;P 500 over the past year, is today's biggest gainer in the index after <a href=\"https://seekingalpha.com/news/3479568-halliburton-tops-estimates-strong-international-demand\" target=\"_blank\">beating Q2 earnings expectations</a> and saying it <a href=\"https://finance.yahoo.com/news/halliburton-cuts-8-north-american-162949724.html\" target=\"_blank\">idled unused fracking equipment</a> and cut 8% of its North American workforce, rising more than 8% for its biggest intraday gain since November 2016.</li><li>CEO Jeff Miller said during today's <a href=\"https://seekingalpha.com/article/4276491-halliburton-company-hal-ceo-jeff-miller-q2-2019-results-earnings-call-transcript\" target=\"_blank\">earnings conference call</a> that the company <a href=\"https://www.reuters.com/article/us-halliburton-results/halliburton-profit-beats-as-company-cuts-cost-shares-rise-idUSKCN1UH16I\" target=\"_blank\">idled fracking equipment</a> during Q2 and will continue to do so, and has taken steps to cut costs by reorganizing its North American business.</li><li>While Q2 revenues for the Completion and Production unit fell 8% Y/Y, results rose 4% from Q1 and Miller said HAL lifted margins in the segment by cutting costs and maximizing equipment usage.</li><li>\"The magnitude of the improvement in the Completions and Production margin performance\" was encouraging, says Tudor Pickering Holt analyst Byron Pope.</li><li>\"Kudos for being proactive on the stacked equipment in this market versus fighting for share,\" says Goldman Sachs analyst Angie Sedita.</li><li>Despite the improvements, Miller warned that Q3 activity would decline as customers continue to focus on cutting spending.</li><li>Major oilfield services peers also trade higher: <a href='https://seekingalpha.com/symbol/SLB' title='Schlumberger Limited'>SLB</a> <font color=\"green\">+1.1%</font>, <a href='https://seekingalpha.com/symbol/BHGE' title='Baker Hughes, a GE company'>BHGE</a> <font color=\"green\">+2.3%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XOP' title='SPDR S&P Oil & Gas Exploration & Production ETF'>XOP</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/XES' title='SPDR S&P Oil & Gas Equipment & Services ETF'>XES</a>, <a href='https://seekingalpha.com/symbol/GUSH' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 3x Shares ETF'>GUSH</a>, <a href='https://seekingalpha.com/symbol/DRIP' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 3x Shares ETF'>DRIP</a>, <a href='https://seekingalpha.com/symbol/IEO' title='iShares U.S. Oil & Gas Exploration & Production ETF'>IEO</a>, <a href='https://seekingalpha.com/symbol/IEZ' title='iShares U.S. Oil Equipment & Services ETF'>IEZ</a>, <a href='https://seekingalpha.com/symbol/NDP' title='Tortoise Energy Independence Fund'>NDP</a>, <a href='https://seekingalpha.com/symbol/PXE' title='Invesco Dynamic Energy Exploration & Production Portfolio ETF'>PXE</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3479818\" data-linked=\"Halliburton +8% after idling fracking gear, cutting costs\" data-tweet=\"$HAL $SLB $BHGE - Halliburton +8% after idling fracking gear, cutting costs https://seekingalpha.com/news/3479818-halliburtonplus-8-after-idling-fracking-gear-cutting-costs?source=tweet\" data-url=\"https://seekingalpha.com/news/3479818-halliburtonplus-8-after-idling-fracking-gear-cutting-costs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479801\" data-ts=\"1563818182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HOG\" target=\"_blank\">HOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479801-skittish-trading-on-harley-davidson-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skittish trading on Harley-Davidson ahead of earnings</a></h4><ul> <li>Harley-Davidson (<a href='https://seekingalpha.com/symbol/HOG' title='Harley-Davidson, Inc.'>HOG</a> <font color='red'>-1.8%</font>) trades lower a day ahead of the company reporting Q2 earnings and posting a guidance update.</li> <li>UBS thinks Harley will report a 7% to 9% drop in Q2 retail sales, a mark that could put 2019 shipment guidance at risk.</li> <li>Shares of HOG are down 14% since the last time earnings were reported.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479801\" data-linked=\"Skittish trading on Harley-Davidson ahead of earnings\" data-tweet=\"$HOG - Skittish trading on Harley-Davidson ahead of earnings https://seekingalpha.com/news/3479801-skittish-trading-on-harley-davidson-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3479801-skittish-trading-on-harley-davidson-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479794\" data-ts=\"1563818057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479794-aspen-aerogels-leads-energy-materials-gainers-coda-octopus-group-and-hovnanian-enterprises\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aspen Aerogels leads Energy/Materials gainers; Coda Octopus Group and Hovnanian Enterprises only losers</a></h4><ul><li><b>Gainers:</b> Aspen Aerogels (NYSE:<a href='https://seekingalpha.com/symbol/ASPN' title='Aspen Aerogels, Inc.'>ASPN</a>) <font color=\"green\">+8%</font>. Orion Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ORN' title='Orion Group Holdings, Inc.'>ORN</a>) <font color=\"green\">+6%</font>. Intelligent Systems (NYSEMKT:<a href='https://seekingalpha.com/symbol/INS' title='Intelligent Systems Corporation'>INS</a>) <font color=\"green\">+6%</font>. Hebron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> Coda Octopus Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CODA' title='Coda Octopus Group, Inc.'>CODA</a>) <font color=\"red\">-6%</font>. Hovnanian Enterprises (NYSE:<a href='https://seekingalpha.com/symbol/HOV' title='Hovnanian Enterprises, Inc.'>HOV</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479794\" data-linked=\"Aspen Aerogels leads Energy/Materials gainers; Coda Octopus Group and Hovnanian Enterprises only losers\" data-tweet=\"$ASPN $ORN $INS - Aspen Aerogels leads Energy/Materials gainers; Coda Octopus Group and Hovnanian Enterprises only losers https://seekingalpha.com/news/3479794-aspen-aerogels-leads-energy-materials-gainers-coda-octopus-group-and-hovnanian-enterprises?source=tweet\" data-url=\"https://seekingalpha.com/news/3479794-aspen-aerogels-leads-energy-materials-gainers-coda-octopus-group-and-hovnanian-enterprises\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479792\" data-ts=\"1563818008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479792-ftc-will-announce-5b-fb-settlement-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FTC will announce $5B FB settlement - report</a></h4><ul><li>The FTC might announce the settlement with Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook, Inc.'>FB</a>) over its privacy practices this week, according to Dow Jones sources.</li><li>The FTC originally considered a financial penalty in the tens of billions of dollars and elements that would hold CEO Mark Zuckerberg personally responsible, according to a <a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwi27oX7isnjAhWIg1QKHTrADOcQ0PADMAB6BAgAEAU&amp;url=https%3A%2F%2Fwww.washingtonpost.com%2Ftechnology%2F2019%2F07%2F22%2Ffacebook-vs-feds-inside-story-multi-billion-dollar-tech-giants-privacy-war-with-washington%2F&amp;usg=AOvVaw3wxDt82zcHae6h8UUcqSf9\" target=\"_blank\">Washington Post</a> report. FB resisted the government's demands, and the FTC stopped short of the harsher punishments.</li><li>FB shares are <font color=\"green\">up 1.6%</font> to $201.53.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479792\" data-linked=\"FTC will announce $5B FB settlement - report\" data-tweet=\"$FB - FTC will announce $5B FB settlement - report https://seekingalpha.com/news/3479792-ftc-will-announce-5b-fb-settlement-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3479792-ftc-will-announce-5b-fb-settlement-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479758\" data-ts=\"1563816555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADAP\" target=\"_blank\">ADAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479758-adaptimmune-up-10-on-promise-of-low-dose-radiation-to-improve-spear-t-cell-therapy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adaptimmune up 10% on promise of low-dose radiation to improve SPEAR T-cell therapy</a></h4><ul><li>Thinly traded micro cap Adaptimmune Therapeutics plc (<a href='https://seekingalpha.com/symbol/ADAP' title='Adaptimmune Therapeutics plc'>ADAP</a> <font color=\"green\">+10.4%</font>) is up on modestly higher volume, albeit on turnover of only 306K shares, in reaction to the <a href=\"https://seekingalpha.com/pr/17577862-adaptimmune-initiated-radiation-sub-study-enhance-antitumor-activity-seen-adp-a2m4\" target=\"_blank\">initiation </a>of a 10-subject radiation sub-study evaluating its ADP-A2M4 SPEAR T cells in patients with solid tumors.</li><li>The company says published data show that low-dose radiation may enhance T-cell responses in these patients.</li><li>It expects to launch a new trial, SPEARHEAD-1, assessing ADP-A2M4 in sarcoma patients later this year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479758\" data-linked=\"Adaptimmune up 10% on promise of low-dose radiation to improve SPEAR T-cell therapy\" data-tweet=\"$ADAP - Adaptimmune up 10% on promise of low-dose radiation to improve SPEAR T-cell therapy https://seekingalpha.com/news/3479758-adaptimmune-up-10-on-promise-of-low-dose-radiation-to-improve-spear-t-cell-therapy?source=tweet\" data-url=\"https://seekingalpha.com/news/3479758-adaptimmune-up-10-on-promise-of-low-dose-radiation-to-improve-spear-t-cell-therapy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479755\" data-ts=\"1563815714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479755-symantecplus-1_9-on-broadcoms-continuing-interest-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Symantec +1.9% on Broadcom&#39;s continuing interest - report</a></h4><ul><li>StreetInsider <a href=\"https://www.streetinsider.com/Hot+M+and+A/Bankers%2C+Investors+Look+to+Salvage+Broadcom+%28AVGO%29Symantec+%28SYMC%29+Deal+-+Sources/15722640.html\" target=\"_blank\">sources</a> say Broadcom (<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Inc.'>AVGO</a> <font color='green'>+2.1%</font>) is still interested in acquiring Symantec (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>) with unidentified bankers on both sides working towards a deal.</li><li>The sources say a deal would likely happen if AVGO came back with a $28/share offer, which was the sticking point in the prior negotiations.</li><li>Symantec shares are <font color=\"green\">up 1.9%</font> to $22.70.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479755\" data-linked=\"Symantec +1.9% on Broadcom&#39;s continuing interest - report\" data-tweet=\"$AVGO $NLOK - Symantec +1.9% on Broadcom&#39;s continuing interest - report https://seekingalpha.com/news/3479755-symantecplus-1_9-on-broadcoms-continuing-interest-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3479755-symantecplus-1_9-on-broadcoms-continuing-interest-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479746\" data-ts=\"1563815590\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDOC\" target=\"_blank\">TDOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479746-teladoc-up-2_5-on-positive-mention-on-cnbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teladoc up 2.5% on positive mention on CNBC</a></h4><ul><li>Teladoc (<a href='https://seekingalpha.com/symbol/TDOC' title='Teladoc Health, Inc.'>TDOC</a> <font color=\"green\">+2.5%</font>) is up on modestly higher volume in apparent response to positive comments by investor Josh Brown on CNBC's Halftime Report.</li><li>The company is scheduled to release Q2 results after the close on Wednesday, July 31. Consensus view is a loss/share of ($0.41) on revenue of $129.6M.</li><li>Shares have rallied over <font color=\"green\">30%</font> since early June.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479746\" data-linked=\"Teladoc up 2.5% on positive mention on CNBC\" data-tweet=\"$TDOC - Teladoc up 2.5% on positive mention on CNBC https://seekingalpha.com/news/3479746-teladoc-up-2_5-on-positive-mention-on-cnbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3479746-teladoc-up-2_5-on-positive-mention-on-cnbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479752\" data-ts=\"1563815535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IIPR\" target=\"_blank\">IIPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479752-innovative-industrial-falls-18-since-announcing-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Innovative Industrial falls 18% since announcing capital raise</a></h4><ul><li>Innovative Industrial Properties (NYSE:<a href='https://seekingalpha.com/symbol/IIPR' title='Innovative Industrial Properties, Inc.'>IIPR</a>)<font color=\"red\"> slumps 8.1%</font>; the stock has declined 18% from July 11, the day it started a 1.25M-share stock offering.</li><li>Some 858K shares have changed hands so far today, exceeding its three-month average daily volume of 474K.</li><li>YTD, IIPR has risen 172%, far exceeding the S&amp;P 500's 19% climb in the same time period.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3477423-innovative-industrial-properties-prices-follow-offering-126-per-share\" target=\"_blank\">Innovative Industrial Properties prices follow-on offering at $126 per share</a> (July 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3479752\" data-linked=\"Innovative Industrial falls 18% since announcing capital raise\" data-tweet=\"$IIPR - Innovative Industrial falls 18% since announcing capital raise https://seekingalpha.com/news/3479752-innovative-industrial-falls-18-since-announcing-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3479752-innovative-industrial-falls-18-since-announcing-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479749\" data-ts=\"1563815474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RL\" target=\"_blank\">RL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479749-ralph-lauren-falls-after-global-fashion-superstar-departs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ralph Lauren falls after global fashion superstar departs</a></h4><ul> <li>Ralph Lauren (<a href='https://seekingalpha.com/symbol/RL' title='Ralph Lauren Corporation'>RL</a> <font color='red'>-1.6%</font>) trades lower after the company <a href=\"https://fashionunited.uk/news/people/valerie-hermann-to-step-down-from-ralph-lauren/2019072244363\" target=\"_blank\">confirms</a> the departure of well-known Global Brands President Valerie Hermann.</li> <li>Hermann has been largely focused on the Ralph Lauren brand during her time at the company.</li> <li>A replacement for Hermann has not been announced.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479749\" data-linked=\"Ralph Lauren falls after global fashion superstar departs\" data-tweet=\"$RL - Ralph Lauren falls after global fashion superstar departs https://seekingalpha.com/news/3479749-ralph-lauren-falls-after-global-fashion-superstar-departs?source=tweet\" data-url=\"https://seekingalpha.com/news/3479749-ralph-lauren-falls-after-global-fashion-superstar-departs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479735\" data-ts=\"1563814856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479735-aspen-aerogels-leads-industrial-gainers-coda-octopus-only-loser\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aspen Aerogels leads industrial gainers; Coda Octopus only loser</a></h4><ul><li><b>Gainers: </b>Aspen Aerogels (NYSE:<a href='https://seekingalpha.com/symbol/ASPN' title='Aspen Aerogels, Inc.'>ASPN</a>) <font color=\"green\">+8%</font>. ToughBuilt Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/TBLT' title='ToughBuilt Industries, Inc.'>TBLT</a>) <font color=\"green\">+7%</font>. Intelligent Systems (NYSEMKT:<a href='https://seekingalpha.com/symbol/INS' title='Intelligent Systems Corporation'>INS</a>) <font color=\"green\">+7%</font>. Orion Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ORN' title='Orion Group Holdings, Inc.'>ORN</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Coda Octopus Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CODA' title='Coda Octopus Group, Inc.'>CODA</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479735\" data-linked=\"Aspen Aerogels leads industrial gainers; Coda Octopus only loser\" data-tweet=\"$ASPN $TBLT $INS - Aspen Aerogels leads industrial gainers; Coda Octopus only loser https://seekingalpha.com/news/3479735-aspen-aerogels-leads-industrial-gainers-coda-octopus-only-loser?source=tweet\" data-url=\"https://seekingalpha.com/news/3479735-aspen-aerogels-leads-industrial-gainers-coda-octopus-only-loser\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479734\" data-ts=\"1563814680\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479734-condor-hospitality-trust-leads-financial-gainers-golden-bull-and-cadence-bancorp-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Condor Hospitality Trust leads financial gainers, Golden Bull and Cadence Bancorp among losers</a></h4><ul><li><b>Gainers:</b> Condor Hospitality Trust (NYSEMKT:<a href='https://seekingalpha.com/symbol/CDOR' title='Condor Hospitality Trust, Inc.'>CDOR</a>) <font color=\"green\">+33%</font>. MFS California Municipal Fund (NYSEMKT:<a href='https://seekingalpha.com/symbol/CCA' title='MFS California Municipal Fund'>CCA</a>) <font color=\"green\">+8%</font>. Power REIT (NYSEMKT:<a href='https://seekingalpha.com/symbol/PW' title='Power REIT'>PW</a>) <font color=\"green\">+7%</font>. FlexShopper (NASDAQ:<a href='https://seekingalpha.com/symbol/FPAY' title='FlexShopper, Inc.'>FPAY</a>) <font color=\"green\">+7%</font>. Puyi (NASDAQ:<a href='https://seekingalpha.com/symbol/PUYI' title='Puyi Inc.'>PUYI</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> Cadence Bancorporation (NYSE:<a href='https://seekingalpha.com/symbol/CADE' title='Cadence Bancorporation'>CADE</a>) <font color=\"red\">-17%</font>. LM Funding America (NASDAQ:<a href='https://seekingalpha.com/symbol/LMFA' title='LM Funding America, Inc.'>LMFA</a>) <font color=\"red\">-11%</font>. Innovative Industrial Properties (NYSE:<a href='https://seekingalpha.com/symbol/IIPR' title='Innovative Industrial Properties, Inc.'>IIPR</a>) <font color=\"red\">-8%</font>. Golden Bull (NASDAQ:<a href='https://seekingalpha.com/symbol/DNJR' title='Golden Bull Limited'>DNJR</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479734\" data-linked=\"Condor Hospitality Trust leads financial gainers, Golden Bull and Cadence Bancorp among losers\" data-tweet=\"$CDOR $CCA $PW - Condor Hospitality Trust leads financial gainers, Golden Bull and Cadence Bancorp among losers https://seekingalpha.com/news/3479734-condor-hospitality-trust-leads-financial-gainers-golden-bull-and-cadence-bancorp-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3479734-condor-hospitality-trust-leads-financial-gainers-golden-bull-and-cadence-bancorp-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479729\" data-ts=\"1563813172\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479729-microcaps-mostly-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among midday movers</a></h4><ul><li><strong>Gainers: </strong>Peak Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/SKIS' title='Peak Resorts, Inc.'>SKIS</a>) <font color=\"green\">+113%</font>. Condor Hospitality Trust (NYSEMKT:<a href='https://seekingalpha.com/symbol/CDOR' title='Condor Hospitality Trust, Inc.'>CDOR</a>) <font color=\"green\">+32%</font>. Lannett Company (NYSE:<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc.'>LCI</a>) <font color=\"green\">+26%</font>. Acasti Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma Inc.'>ACST</a>) <font color=\"green\">+20%</font>. Horizon Global Corporation (NYSE:<a href='https://seekingalpha.com/symbol/HZN' title='Horizon Global Corporation'>HZN</a>) <font color=\"green\">+15%</font>. Guardion Health Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GHSI' title='Guardion Health Sciences, Inc.'>GHSI</a>) <font color=\"green\">+12%</font>. Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals, Inc.'>ZYNE</a>) <font color=\"green\">+14%</font>. Navios Maritime Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NM' title='Navios Maritime Holdings Inc.'>NM</a>) <font color=\"green\">+15%</font>. Soliton (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a>) <font color=\"green\">+14%</font>. Rekor Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/REKR' title='Rekor Systems, Inc.'>REKR</a>) <font color=\"green\">+13%</font>.</li> <li><strong>Losers: </strong>Intec Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/NTEC' title='Intec Pharma Ltd.'>NTEC</a>) <font color=\"red\">-80%</font>. Xenetic Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>) <font color=\"red\">-21%</font>. SSLJ.com Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/YGTY' title='SSLJ.com Limited'>YGTY</a>) <font color=\"red\">-20%</font>. Torchlight Energy Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/TRCH' title='Torchlight Energy Resources, Inc.'>TRCH</a>) <font color=\"red\">-18%</font>. PaySign (NASDAQ:<a href='https://seekingalpha.com/symbol/PAYS' title='PaySign, Inc.'>PAYS</a>) <font color=\"red\">-17%</font>. Cadence Bancorporation (NYSE:<a href='https://seekingalpha.com/symbol/CADE' title='Cadence Bancorporation'>CADE</a>) <font color=\"red\">-17%</font>. Advaxis (NASDAQ:<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis, Inc.'>ADXS</a>) <font color=\"red\">-15%</font>. Neuralstem (NASDAQ:<a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a>) <font color=\"red\">-16%</font>. Xcel Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a>) <font color=\"red\">-14%</font>. MarineMax (NYSE:<a href='https://seekingalpha.com/symbol/HZO' title='MarineMax, Inc.'>HZO</a>) <font color=\"red\">-14%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479729\" data-linked=\"Microcaps mostly among midday movers\" data-tweet=\"$SKIS $CDOR $LCI - Microcaps mostly among midday movers https://seekingalpha.com/news/3479729-microcaps-mostly-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3479729-microcaps-mostly-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479727\" data-ts=\"1563812959\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LCI\" target=\"_blank\">LCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479727-lannettplus-27-clears-consolidation-on-heavy-volume\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lannett (+27%) clears consolidation on heavy volume</a></h4><ul><li>Generic drug maker Lannett Company (<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc.'>LCI</a> <font color=\"green\">+26.8%</font>) is up on a 4x surge in volume, clearing near-term resistance of ~$6.25.</li><li>No news has hit the wires that would account for the action. A couple of weeks ago, it inked a <a href=\"https://seekingalpha.com/news/3476142-lannett-inks-deal-levothyroxine\" target=\"_blank\">deal </a>for a future supply of levothyroxine sodium tablets that will commence no later than August 1, 2022.</li><li>The company, along with a number of its generic drug compatriots, has been under pressure from allegations of widespread <a href=\"https://seekingalpha.com/news/3462837-teva-8-percent-premarket-60-minutes-piece-alleged-price-fixing\" target=\"_blank\">price-fixing</a> in the industry.</li><li>On the working capital front, at the end of March it had $205.2M in cash and equivalents while operations generated $181.7M during the first three fiscal quarters, although an asset impairment charge (+$369.5M) accounted for the bulk of the positive cash flow.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479727\" data-linked=\"Lannett (+27%) clears consolidation on heavy volume\" data-tweet=\"$LCI - Lannett (+27%) clears consolidation on heavy volume https://seekingalpha.com/news/3479727-lannettplus-27-clears-consolidation-on-heavy-volume?source=tweet\" data-url=\"https://seekingalpha.com/news/3479727-lannettplus-27-clears-consolidation-on-heavy-volume\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479721\" data-ts=\"1563811662\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUI\" target=\"_blank\">CUI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479721-cui-global-secures-purchase-order-for-services-in-excess-of-900k\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CUI Global secures purchase order for services in excess of $900k</a></h4><ul><li>CUI Global (<a href='https://seekingalpha.com/symbol/CUI' title='CUI Global, Inc.'>CUI</a> <font color=\"green\">+3.7%</font>) subsidiary, Orbital Gas Systems has been <a href=\"https://seekingalpha.com/pr/17577640-cui-global-subsidiary-orbital-gas-systems-secures-purchase-order-services-excess-900000-major\" target=\"_blank\">awarded</a> a purchase order valued at more than $900k under an existing framework agreement with a major UK gas network operator.</li><li>Orbital will be undertaking the service, repair and calibration of equipment installed at 23 of the Operator's sites in the UK for a period of one year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479721\" data-linked=\"CUI Global secures purchase order for services in excess of $900k\" data-tweet=\"$CUI - CUI Global secures purchase order for services in excess of $900k https://seekingalpha.com/news/3479721-cui-global-secures-purchase-order-for-services-in-excess-of-900k?source=tweet\" data-url=\"https://seekingalpha.com/news/3479721-cui-global-secures-purchase-order-for-services-in-excess-of-900k\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479719\" data-ts=\"1563811288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479719-beyond-meat-leads-consumer-gainers-china-xd-plastics-and-new-age-beverages-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Beyond Meat leads consumer gainers; China XD Plastics and New Age Beverages among losers</a></h4><ul><li><b>Gainers: </b>Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) <font color=\"green\">+9%</font>. Mannatech (NASDAQ:<a href='https://seekingalpha.com/symbol/MTEX' title='Mannatech, Incorporated'>MTEX</a>) <font color=\"green\">+8%</font>. Village Farms International (NASDAQ:<a href='https://seekingalpha.com/symbol/VFF' title='Village Farms International, Inc.'>VFF</a>) <font color=\"green\">+7%</font>. Koninklijke Philips (NYSE:<a href='https://seekingalpha.com/symbol/PHG' title='Koninklijke Philips N.V.'>PHG</a>) <font color=\"green\">+6%</font>. Kontoor Brands (NYSE:<a href='https://seekingalpha.com/symbol/KTB' title='Kontoor Brands, Inc.'>KTB</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Xcel Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a>) <font color=\"red\">-12%</font>. MasterCraft Boat Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MCFT' title='MasterCraft Boat Holdings, Inc.'>MCFT</a>) <font color=\"red\">-9%</font>. China XD Plastics Company (NASDAQ:<a href='https://seekingalpha.com/symbol/CXDC' title='China XD Plastics Company Limited'>CXDC</a>) <font color=\"red\">-8%</font>. Malibu Boats (NASDAQ:<a href='https://seekingalpha.com/symbol/MBUU' title='Malibu Boats, Inc.'>MBUU</a>) <font color=\"red\">-8%</font>. New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479719\" data-linked=\"Beyond Meat leads consumer gainers; China XD Plastics and New Age Beverages among losers\" data-tweet=\"$BYND $MTEX $VFF - Beyond Meat leads consumer gainers; China XD Plastics and New Age Beverages among losers https://seekingalpha.com/news/3479719-beyond-meat-leads-consumer-gainers-china-xd-plastics-and-new-age-beverages-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3479719-beyond-meat-leads-consumer-gainers-china-xd-plastics-and-new-age-beverages-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479717\" data-ts=\"1563811124\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479717-etsy-to-acquire-reverb\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Etsy to acquire Reverb</a></h4><ul><li>Etsy (<a href='https://seekingalpha.com/symbol/ETSY' title='Etsy, Inc.'>ETSY</a> <font color=\"green\">+2.5%</font>) to <a href=\"https://seekingalpha.com/pr/17578055-etsy-acquire-reverb-leading-online-marketplace-new-used-vintage-musical-instruments\" target=\"_blank\">acquire</a> Reverb Holdings, Inc., a privately held marketplace for new, used and vintage music gear for $275M in cash.</li><li>The transaction is currently expected to close in late 3Q19 or early 4Q19.</li><li>Etsy plans to provide financial guidance following the completion of the transaction.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479717\" data-linked=\"Etsy to acquire Reverb\" data-tweet=\"$ETSY - Etsy to acquire Reverb https://seekingalpha.com/news/3479717-etsy-to-acquire-reverb?source=tweet\" data-url=\"https://seekingalpha.com/news/3479717-etsy-to-acquire-reverb\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479716\" data-ts=\"1563810779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPIX\" target=\"_blank\">IPIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479716-innovation-pharma-up-58-on-brilacidin-license-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Innovation Pharma up 58% on Brilacidin license deal</a></h4><ul><li>Nano cap Innovation Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IPIX' title='Innovation Pharmaceuticals Inc.'>OTCQB:IPIX</a> <font color=\"green\">+58%</font>) is up on almost triple normal volume in reaction to its <a href=\"https://seekingalpha.com/pr/17578212-innovation-pharmaceuticals-announces-license-agreement-alfasigma-s-p-development\" target=\"_blank\">out-licensing agreement</a> with Bologna, Italy-based <a href=\"https://www.alfasigma.com/en/company\" target=\"_blank\">Alfasigma S.p.A.</a> for global rights to develop and commercialize locally administered (foam, gel, enema) Brilacidin for the treatment of ulcerative proctitis/ulcerative proctosigmoiditis.</li><li>Under the terms of the agreement, IPIX will receive up to $24M in upfront and milestone payments and a 6% royalty on net sales. Alfasigma also has a right of first refusal for the use of Brilacidin in more extensive types of inflammatory bowel disease like ulcerative colitis and Crohn's and a right of first negotiation for Brilacidin in other gastrointestinal indications.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479716\" data-linked=\"Innovation Pharma up 58% on Brilacidin license deal\" data-tweet=\"$IPIX - Innovation Pharma up 58% on Brilacidin license deal https://seekingalpha.com/news/3479716-innovation-pharma-up-58-on-brilacidin-license-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3479716-innovation-pharma-up-58-on-brilacidin-license-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479711\" data-ts=\"1563809772\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNK\" target=\"_blank\">MNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479711-mallinckrodt-continues-slide-down-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mallinckrodt continues slide, down 6%</a></h4><ul><li>Mallinckrodt (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt plc'>MNK</a> <font color=\"red\">-6.1%</font>) slumps on modestly higher volume. Shares have sold off almost <font color=\"red\">30%</font> in a month.</li><li>On Friday, it terminated its $250M receivables securitization facility after repaying $200M of borrowings. Bloomberg Intelligence's Mike Holland says the elimination of cheap financing under the facility is a negative, adding that the company has now lost half of the ~$1B of liquidity it had at the start of the year.</li><li>Last week, it <a href=\"https://seekingalpha.com/news/3478283-mallinckrodt-bails-mid-stage-study-acthar-gel-als\" target=\"_blank\">terminated </a>a study of Acthar Gel in ALS due to a safety signal and uncertain efficacy.</li><li>SA Authors rate the stock <a href=\"https://seekingalpha.com/symbol/MNK/ratings/author-ratings#filter=all\" target=\"_blank\">Neutral </a>as do <a href=\"https://seekingalpha.com/symbol/MNK/ratings/sell-side-ratings\" target=\"_blank\">Sell Siders</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479711\" data-linked=\"Mallinckrodt continues slide, down 6%\" data-tweet=\"$MNK - Mallinckrodt continues slide, down 6% https://seekingalpha.com/news/3479711-mallinckrodt-continues-slide-down-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3479711-mallinckrodt-continues-slide-down-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479710\" data-ts=\"1563809661\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAKD\" target=\"_blank\">NAKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479710-naked-brand-slumps-after-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Naked Brand slumps further after share offering</a></h4><ul> <li>Naked Brand (<a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a> <font color='red'>-36.6%</font>) plummets after the company <a href=\"https://ir.nakedbrands.com/press-releases/detail/118/naked-brand-group-limited-announces-pricing-of-registered\" target=\"_blank\">discloses</a> that it entered into securities purchase agreements with certain institutional investors, providing for the purchase and sale of 15.75M shares at a price of $0.10 per share in a registered direct offering.</li><li>The offering will result in total gross proceeds to the company of approximately $1.575M.</li> <li>The company has also agreed to issue to the investors unregistered warrants to purchase up to 15.75M ordinary shares. The warrants have an exercise price of $0.10 per ordinary share, will be exercisable immediately and will expire five and one-half years following the date of issuance.</li><li>Naked intends to use the net proceeds from the offering for working capital and other general corporate purposes.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3479710\" data-linked=\"Naked Brand slumps further after share offering\" data-tweet=\"$NAKD - Naked Brand slumps further after share offering https://seekingalpha.com/news/3479710-naked-brand-slumps-after-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3479710-naked-brand-slumps-after-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479709\" data-ts=\"1563809427\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BYND\" target=\"_blank\">BYND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479709-beyond-meat-sizzles-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Beyond Meat sizzles into earnings</a></h4><ul> <li>Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) is <font color=\"green\">up 9.7%</font> as shares look poised to make another run at $200 ahead of the food company's earnings report on July 29.</li> <li>While analysts have been dialing down expectations for Beyond Meat, traders appear to be betting that a short squeeze is setting up similar to the huge rally that followed Q1 earnings.</li> <li>For what it's worth, Oppenheimer is out with a gentle reminder that BYND has replaced Tesla as a cult stock.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479709\" data-linked=\"Beyond Meat sizzles into earnings\" data-tweet=\"$BYND - Beyond Meat sizzles into earnings https://seekingalpha.com/news/3479709-beyond-meat-sizzles-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3479709-beyond-meat-sizzles-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>145&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479705\" data-ts=\"1563808704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAGS\" target=\"_blank\">PAGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479705-pagseguro-gains-3_5-after-credit-suisse-turns-bullish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PagSeguro gains 3.5% after Credit Suisse turns bullish</a></h4><ul><li>PagSeguro Digital (NYSE:<a href='https://seekingalpha.com/symbol/PAGS' title='PagSeguro Digital Ltd.'>PAGS</a>) <font color=\"green\">advances 3.5% </font>after Credit Suisse analyst Marcelo Telles <a href=\"https://www.marketbeat.com/ratings/USA/latest/\" target=\"_blank\">upgrades</a> the stock to outperform from underperform.</li><li>Boosts price target to $60 from $25.</li><li>Quant rating <a href=\"https://seekingalpha.com/symbol/PAGS/ratings/quant-ratings\" target=\"_blank\">Neutral</a>; Sell-Side average rating <a href=\"https://seekingalpha.com/symbol/PAGS/ratings/sell-side-ratings\" target=\"_blank\">Outperform</a> (9 Buy, 5 Outperform, 2 Hold, 1 Sell).</li></ul><div class=\"tiny-share-widget\" data-id=\"3479705\" data-linked=\"PagSeguro gains 3.5% after Credit Suisse turns bullish\" data-tweet=\"$PAGS - PagSeguro gains 3.5% after Credit Suisse turns bullish https://seekingalpha.com/news/3479705-pagseguro-gains-3_5-after-credit-suisse-turns-bullish?source=tweet\" data-url=\"https://seekingalpha.com/news/3479705-pagseguro-gains-3_5-after-credit-suisse-turns-bullish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479703\" data-ts=\"1563808140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNCAF\" target=\"_blank\">SNCAF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479703-snc-lavalin-announces-shakeup-warns-on-profit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SNC-Lavalin announces shakeup, warns on profit</a></h4><ul><li>SNC-Lavalin (<a href='https://seekingalpha.com/symbol/SNCAF' title='SNC-Lavalin Group Inc.'>OTCPK:SNCAF</a> <font color='red'>-7.2%</font>) sinks after <a href=\"https://business.financialpost.com/news/fp-street/snc-lavalin-says-exploring-all-options-for-resource-business-in-major-shakeup\" target=\"_blank\">withdrawing its full-year forecast</a> and warning of significantly lower results, as it considers strategic options for its resources unit.</li><li>SNC, which in February forecast FY 2019 EPS of $3.00-$3.20, says it will reorganize its resources and  infrastructure construction segments into a separate business, and says it will explore all options including a sale for the resources segment, particularly its oil and gas business.</li><li>The engineering and construction firm says it plans to exit \"lump-sum turnkey contracting,\" calling it \"the root cause of the company's performance issues.</li><li>\"By exiting such contracting... we are tackling the problem at the source,  and as a result we expect to see a material improvement in the  predictability and clarity of our results,\" says interim CEO Ian Edwards, who was appointed to the job a little over a month ago.</li><li>SNC says it will take a $1.9B writedown on Q2 earnings related to goodwill impairment and intangible assets in the oil and gas business, and expects to post a Q2 adjusted core loss of $150M-$175M in its main engineering and construction business.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479703\" data-linked=\"SNC-Lavalin announces shakeup, warns on profit\" data-tweet=\"$SNCAF - SNC-Lavalin announces shakeup, warns on profit https://seekingalpha.com/news/3479703-snc-lavalin-announces-shakeup-warns-on-profit?source=tweet\" data-url=\"https://seekingalpha.com/news/3479703-snc-lavalin-announces-shakeup-warns-on-profit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479698\" data-ts=\"1563807782\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479698-arbutus-biopharma-and-zynerba-pharmaceuticals-among-healthcare-gainers-neuralstem-and-advaxis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arbutus Biopharma and Zynerba Pharmaceuticals among healthcare gainers; Neuralstem and Advaxis among losers</a></h4><ul><li><b>Gainers: </b>Soliton (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a>) <font color=\"green\">+16%</font>. Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals, Inc.'>ZYNE</a>) <font color=\"green\">+14%</font>. Guardion Health Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GHSI' title='Guardion Health Sciences, Inc.'>GHSI</a>) <font color=\"green\">+12%</font>. Acasti Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma Inc.'>ACST</a>) <font color=\"green\">+11%</font>. Arbutus Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ABUS' title='Arbutus Biopharma Corporation'>ABUS</a>) <font color=\"green\">+10%</font>.</li><li><b>Losers: </b>Intec Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/NTEC' title='Intec Pharma Ltd.'>NTEC</a>) <font color=\"red\">-84%</font>. Xenetic Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>) <font color=\"red\">-23%</font>. Neuralstem (NASDAQ:<a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a>) <font color=\"red\">-17%</font>. Advaxis (NASDAQ:<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis, Inc.'>ADXS</a>) <font color=\"red\">-15%</font>. Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a>) <font color=\"red\">-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479698\" data-linked=\"Arbutus Biopharma and Zynerba Pharmaceuticals among healthcare gainers; Neuralstem and Advaxis among losers\" data-tweet=\"$SOLY $ZYNE $GHSI - Arbutus Biopharma and Zynerba Pharmaceuticals among healthcare gainers; Neuralstem and Advaxis among losers https://seekingalpha.com/news/3479698-arbutus-biopharma-and-zynerba-pharmaceuticals-among-healthcare-gainers-neuralstem-and-advaxis?source=tweet\" data-url=\"https://seekingalpha.com/news/3479698-arbutus-biopharma-and-zynerba-pharmaceuticals-among-healthcare-gainers-neuralstem-and-advaxis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479695\" data-ts=\"1563807623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479695-dish-disney-stave-off-former-fox-channel-blackout-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dish, Disney stave off former Fox channel blackout with more talks</a></h4><ul>   <li>Disney (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color=\"green\">+0.6%</font>) and Dish Network (<a href=\"http://seekingalpha.com/symbol/DISH\" target=\"_blank\">DISH</a> <font color=\"green\">+1.8%</font>) have <a href=\"https://www.hollywoodreporter.com/news/fx-national-geographic-blackout-averted-dish-network-1225977?utm_medium=social&amp;utm_source=twitter\" target=\"_blank\">avoided a blackout</a> of former Fox networks -- for now -- as a midnight deadline passed with the two companies continuing to talk.</li>    <li>There's not yet a deal for Dish to continue carriage of FX, FXX, FXM, National Geographic, and National Geographic Wild, networks that Disney acquired in its Fox media asset takeover.</li>    <li>Last week, a dispute between Dish and Meredith led to location stations in 12 markets being blacked out.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479695\" data-linked=\"Dish, Disney stave off former Fox channel blackout with more talks\" data-tweet=\"$DIS $DISH - Dish, Disney stave off former Fox channel blackout with more talks https://seekingalpha.com/news/3479695-dish-disney-stave-off-former-fox-channel-blackout-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3479695-dish-disney-stave-off-former-fox-channel-blackout-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479693\" data-ts=\"1563807195\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479693-microsoft-settles-anti-bribery-charges\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microsoft settles anti-bribery charges</a></h4><ul><li>Microsoft (<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a> <font color='green'>+1.3%</font>) <a href=\"https://www.reuters.com/article/us-microsoft-settlement/microsoft-settles-u-s-charges-it-violated-anti-bribery-law-accepts-criminal-fine-sec-idUSKCN1UH1P3\" target=\"_blank\">will pay </a>more than $25M, including an $8.75M criminal fine for its Hungarian unit. MSFT will pay $16.6M to the SEC for related civil charges.</li><li>The tech giant doesn't admit wrongdoing in the settlements, which are related to books and records violations of the federal Foreign Corrupt Practices Act.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479693\" data-linked=\"Microsoft settles anti-bribery charges\" data-tweet=\"$MSFT - Microsoft settles anti-bribery charges https://seekingalpha.com/news/3479693-microsoft-settles-anti-bribery-charges?source=tweet\" data-url=\"https://seekingalpha.com/news/3479693-microsoft-settles-anti-bribery-charges\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479688\" data-ts=\"1563806976\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JSTLF\" target=\"_blank\">JSTLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479688-just-eat-slumps-amid-report-of-reorg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Just Eat slumps amid report of reorg</a></h4><ul> <li>Just Eat (<a href='https://seekingalpha.com/symbol/JSTLF' title='Just Eat plc'>OTC:JSTLF</a>) trades lower after firing off a round of <a href=\"https://techcrunch.com/2019/07/22/just-eat-layoffs/\" target=\"_blank\">layoffs</a> in the U.K. and Ireland as part of a corporate reset.</li> <li>TechCrunch reports the Just Eat reorganization includes the merging of the customer and restaurant operation teams.</li> <li>Just Eat has faced increased pressure after Amazon took a position in Deliveroo.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479688\" data-linked=\"Just Eat slumps amid report of reorg\" data-tweet=\"$JSTLF - Just Eat slumps amid report of reorg https://seekingalpha.com/news/3479688-just-eat-slumps-amid-report-of-reorg?source=tweet\" data-url=\"https://seekingalpha.com/news/3479688-just-eat-slumps-amid-report-of-reorg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479685\" data-ts=\"1563806490\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479685-microsoft-investing-1b-in-openai\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microsoft investing $1B in OpenAI</a></h4><ul><li>Microsoft (<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a> <font color='green'>+1.6%</font>) <a href=\"https://www.reuters.com/article/us-microsoft-openai/microsoft-to-invest-1-billion-in-openai-idUSKCN1UH1H9\" target=\"_blank\">investment</a> in OpenAI comes with a multiyear partnership to develop AI supercomputing technology on Azure.</li><li>OpenAI was launched in 2015 as a non-profit but earlier this year created a related, for-profit entity.</li><li>OpenAI says the Microsoft investment will help it pursue artificial general intelligence.</li><li>Under the partnership, OpenAI will move many of its services to Azure and Microsoft will be its preferred partner for commercializing new services.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479685\" data-linked=\"Microsoft investing $1B in OpenAI\" data-tweet=\"$MSFT - Microsoft investing $1B in OpenAI https://seekingalpha.com/news/3479685-microsoft-investing-1b-in-openai?source=tweet\" data-url=\"https://seekingalpha.com/news/3479685-microsoft-investing-1b-in-openai\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479683\" data-ts=\"1563806354\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HOTH\" target=\"_blank\">HOTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479683-hoth-up-9-on-positive-biolexa-effect-on-diabetic-skin-ulcers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hoth up 9% on positive BioLexa effect on diabetic skin ulcers</a></h4><ul><li>Ultra-thinly traded nano cap Hoth Therapeutics (<a href='https://seekingalpha.com/symbol/HOTH' title='Hoth Therapeutics, Inc.'>HOTH</a>) is up <font color=\"green\">9%</font>, albeit on only 369 shares, on the heels of <a href=\"https://seekingalpha.com/pr/17577880-hoth-therapeutics-inc-announces-positive-results-pilot-study-biolexa-diabetic-skin-ulcers\" target=\"_blank\">positive results</a> from a pilot study of BioLexa for patients with diabetic skin ulcers.</li><li>The aim of the animal study in mice was to establish foundational protocols for human studies, including optimizing the method of application and optimizing the <em>Staphylococcus aureus</em> inoculation dose to achieve biofilm growth in the wound.</li><li>Preliminary results \"suggested\" a treatment benefit compared to placebo. Most of the treated wounds closed completely with new growth of epithelial cells.</li><li>BioLexa is a topical formulation of a zinc chelator and the antibiotic gentamicin.</li><li>Development is ongoing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479683\" data-linked=\"Hoth up 9% on positive BioLexa effect on diabetic skin ulcers\" data-tweet=\"$HOTH - Hoth up 9% on positive BioLexa effect on diabetic skin ulcers https://seekingalpha.com/news/3479683-hoth-up-9-on-positive-biolexa-effect-on-diabetic-skin-ulcers?source=tweet\" data-url=\"https://seekingalpha.com/news/3479683-hoth-up-9-on-positive-biolexa-effect-on-diabetic-skin-ulcers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479682\" data-ts=\"1563806286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479682-boating-stocks-in-reverse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boating stocks in reverse</a></h4><ul> <li>Investors and analysts are paying quite a bit of attention to weak boating sales data that came out on Friday. The wave of downgrades within the sector today include Raymond James on MCFT, MBUU and HZO (Market Perform from Strong Buy) and JPMorgan on Brunswick (Neutral from Overweight).</li> <li>MarineMax (<a href='https://seekingalpha.com/symbol/HZO' title='MarineMax, Inc.'>HZO</a> <font color='red'>-10.9%</font>), Malibu Boats (<a href='https://seekingalpha.com/symbol/MBUU' title='Malibu Boats, Inc.'>MBUU</a> <font color='red'>-6.7%</font>) and MasterCraft Boat Holdings (<a href='https://seekingalpha.com/symbol/MCFT' title='MasterCraft Boat Holdings, Inc.'>MCFT</a> <font color='red'>-9.8%</font>) are at or near 52-week lows, while Brunswick (<a href='https://seekingalpha.com/symbol/BC' title='Brunswick Corporation'>BC</a> <font color='red'>-4.8%</font>) and Marine Products (<a href='https://seekingalpha.com/symbol/MPX' title='Marine Products Corporation'>MPX</a> <font color='red'>-1.3%</font>) also notably lower.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3479682\" data-linked=\"Boating stocks in reverse\" data-tweet=\"$HZO $MBUU $MCFT - Boating stocks in reverse https://seekingalpha.com/news/3479682-boating-stocks-in-reverse?source=tweet\" data-url=\"https://seekingalpha.com/news/3479682-boating-stocks-in-reverse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479671\" data-ts=\"1563804899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479671-vales-q2-iron-ore-output-tumbles-third\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vale&#39;s Q2 iron ore output tumbles more than a third</a></h4><ul><li>Vale (<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='red'>-1.6%</font>) reports a <a href=\"https://www.reuters.com/article/us-vale-sa-production/vale-second-quarter-iron-ore-output-nosedives-33-8-following-brazil-dam-break-idUSKCN1UH1EL\" target=\"_blank\">34% Y/Y drop in Q2 iron ore production</a> to 64M metric tons, as several major mines including Brucutu, its largest mine in Minas Gerais state, were at least partially shuttered  for all or most of the quarter following January's deadly tailings dam collapse.</li><li>The world's top iron ore exporter also says Q2 sales of the raw material fell 15.5% to 61.9M mt, and production at its giant S11D mine in northern Brazil was hurt by \"abnormal rain.\"</li><li>But Vale reaffirms previous guidance for full-year iron ore and pellets sales of 307M-332M mt.</li><li>Vale restarted full production at  Brucutu late in the quarter, restoring 30M mt of yearly  capacity, and says another 30M mt may come back on line by year-end using \"dry processing\" methods that avoid the use of hazardous tailings  dams.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479671\" data-linked=\"Vale&#39;s Q2 iron ore output tumbles more than a third\" data-tweet=\"$VALE - Vale&#39;s Q2 iron ore output tumbles more than a third https://seekingalpha.com/news/3479671-vales-q2-iron-ore-output-tumbles-third?source=tweet\" data-url=\"https://seekingalpha.com/news/3479671-vales-q2-iron-ore-output-tumbles-third\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479670\" data-ts=\"1563804790\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479670-scorpio-bulkers-cruises-to-2019-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scorpio Bulkers cruises to 2019 high</a></h4><ul> <li>Scorpio Bulkers (NYSE:<a href='https://seekingalpha.com/symbol/SALT' title='Scorpio Bulkers Inc.'>SALT</a>) <font color=\"green\">rallies 7.62%</font> after posting a narrower-than-anticipated loss in Q2 amid a 19% decline in revenue.</li> <li>Adjusted EBITDA churned up was $70M during the quarter.</li> <li>Scorpio says rates earned by vessels were adversely impacted by a reduction in coal imports in Europe and China, loss of iron ore exports from Vale\u2019s tailing dam failure and continued disruptions from the U.S.-China trade war - while a strong South American grain season and increasing coal exports to India provided support for improving Ultramax and Kamsarmax rates during the quarter.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3479572-scorpio-bulkers-eps-0_58\" target=\"_blank\">Scorpio Bulkers EPS of $0.58</a> (July 22)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479670\" data-linked=\"Scorpio Bulkers cruises to 2019 high\" data-tweet=\"$SALT - Scorpio Bulkers cruises to 2019 high https://seekingalpha.com/news/3479670-scorpio-bulkers-cruises-to-2019-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3479670-scorpio-bulkers-cruises-to-2019-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479669\" data-ts=\"1563804734\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADXS\" target=\"_blank\">ADXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479669-advaxis-down-13-on-upsized-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Advaxis down 13% on upsized capital raise</a></h4><ul><li>Thinly traded nano cap Advaxis (<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis, Inc.'>ADXS</a> <font color=\"red\">-13.4%</font>) is down on average volume in early trade in reaction to its planned <a href=\"https://www.sec.gov/Archives/edgar/data/1100397/000149315219010915/forms-1a.htm\" target=\"_blank\">offering</a> of ~11.8M common shares (<a href=\"https://seekingalpha.com/news/3478465-advaxis-11-percent-capital-raise\" target=\"_blank\">up from ~9.6M</a>) and five-year warrants to purchase up to an aggregate of ~8.9M shares (one share + one warrant to purchase 3/4 of a share). Pricing has yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479669\" data-linked=\"Advaxis down 13% on upsized capital raise\" data-tweet=\"$ADXS - Advaxis down 13% on upsized capital raise https://seekingalpha.com/news/3479669-advaxis-down-13-on-upsized-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3479669-advaxis-down-13-on-upsized-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479666\" data-ts=\"1563804316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479666-biocept-up-2-on-beaconlbs-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept up 2% on BeaconLBS deal</a></h4><ul><li>Biocept (<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color=\"green\">+2%</font>) is up on average volume in early trade on the heels of its <a href=\"https://seekingalpha.com/pr/17577937-biocept-announces-laboratory-services-provider-agreement-beaconlbs\" target=\"_blank\">agreement </a>with Beacon Laboratory Benefit Solutions (BeaconLBS) for inclusion in its Labs-of-Choice preferred list of lab services providers that it offers in its solutions to health and managed care companies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479666\" data-linked=\"Biocept up 2% on BeaconLBS deal\" data-tweet=\"$BIOC - Biocept up 2% on BeaconLBS deal https://seekingalpha.com/news/3479666-biocept-up-2-on-beaconlbs-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3479666-biocept-up-2-on-beaconlbs-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479665\" data-ts=\"1563804079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STNE\" target=\"_blank\">STNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479665-stonecoplus-2_3-after-credit-suisse-raises-to-hold\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">StoneCo +2.3% after Credit Suisse raises to hold</a></h4><ul><li>StoneCo (NASDAQ:<a href='https://seekingalpha.com/symbol/STNE' title='StoneCo Ltd.'>STNE</a>) <font color=\"green\">jumps 2.3%</font> after Credit Suisse analyst Marcelo Telles raises his recommendation to neutral from underperform.</li><li>Boosts price target to $36 from $20.</li><li>Before this analyst action, Sell-Side average rating was <a href=\"https://seekingalpha.com/symbol/STNE/ratings/sell-side-ratings\" target=\"_blank\">Hold</a>; SA Authors' average rating <a href=\"https://seekingalpha.com/symbol/STNE/ratings/author-ratings#filter=all\" target=\"_blank\">Bullish</a> (2 Very Bullish, 1 Bearish).</li></ul><div class=\"tiny-share-widget\" data-id=\"3479665\" data-linked=\"StoneCo +2.3% after Credit Suisse raises to hold\" data-tweet=\"$STNE - StoneCo +2.3% after Credit Suisse raises to hold https://seekingalpha.com/news/3479665-stonecoplus-2_3-after-credit-suisse-raises-to-hold?source=tweet\" data-url=\"https://seekingalpha.com/news/3479665-stonecoplus-2_3-after-credit-suisse-raises-to-hold\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479659\" data-ts=\"1563803546\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479659-sprint-t-mobile-rise-on-new-report-merger-ok-is-close\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprint, T-Mobile rise on new report merger OK is close</a></h4><ul>   <li>Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>) is <font color=\"green\">up 4.4%</font> and T-Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a>) <font color=\"green\">up 1%</font> in early going a day after a <a href=\"https://www.foxbusiness.com/financials/t-mobile-sprint-merger-nearing-completion-after-controversial-and-lengthy-negotiations\" target=\"_blank\">Fox Business story</a> echoed other reports that a regulator OK is close for the carriers' $26.5B merger, with a decision that could come by Wednesday.</li>    <li>Assuming that talks keep moving as they have been, regulators told the companies they could make a settlement announcement Wednesday or Thursday or even sooner, according to that report.</li>    <li>Reading one set of tea leaves, an appearance by antitrust chief Makan Delrahim before the Senate antitrust subcommittee set for Tuesday was canceled.</li>    <li>One potential wild card is still Dish Network (<a href=\"http://seekingalpha.com/symbol/DISH\" target=\"_blank\">DISH</a> <font color=\"green\">+0.6%</font>) chief Charlie Ergen, who's said to have agreed to broad outlines on an asset purchase that John Legere and Marcelo Claure can live with -- though a change of heart from Ergen could lead to the Justice Dept. suing to block the deal.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479659\" data-linked=\"Sprint, T-Mobile rise on new report merger OK is close\" data-tweet=\"$S $TMUS $DISH - Sprint, T-Mobile rise on new report merger OK is close https://seekingalpha.com/news/3479659-sprint-t-mobile-rise-on-new-report-merger-ok-is-close?source=tweet\" data-url=\"https://seekingalpha.com/news/3479659-sprint-t-mobile-rise-on-new-report-merger-ok-is-close\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479657\" data-ts=\"1563803475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479657-shiftpixyminus-3_1-post-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ShiftPixy -3.1% post Q3 results</a></h4><ul><li>ShiftPixy (<a href='https://seekingalpha.com/symbol/PIXY' title='ShiftPixy, Inc.'>PIXY</a> <font color=\"red\">-3.1%</font>) reports <a href=\"https://seekingalpha.com/pr/17577910-shiftpixy-inc-reports-fiscal-2019-third-quarter-results\" target=\"_blank\">Q3</a> revenue growth of 52.5% Y/Y to $14.3M.</li><li>Gross profit margin <font color=\"green\">increased 292 bps</font> to 18.88%.</li><li>Gross billings grew 57% Y/Y &amp; 14% Q/Q to $94.2M.</li><li>The average number of worksite employees increased 49.8% Y/Y to 10,860.</li><li>Cash of $2.93M.</li><li>The company has authorized the repurchase of up to 10M shares over an initial period of 18 months, extendable at the Board\u2019s discretion.</li><li>\u201cWe\u2019re quickly penetrating our target markets which is driving rapid growth across key operational and financial metrics.\u201d stated CEO, Scott Absher.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3479578-shiftpixy-eps-misses-0_06-misses-revenue\" target=\"_blank\">ShiftPixy EPS misses by $0.06, misses on revenue</a> (Jul. 22 2019)</li></ul><div class=\"tiny-share-widget\" data-id=\"3479657\" data-linked=\"ShiftPixy -3.1% post Q3 results\" data-tweet=\"$PIXY - ShiftPixy -3.1% post Q3 results https://seekingalpha.com/news/3479657-shiftpixyminus-3_1-post-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3479657-shiftpixyminus-3_1-post-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479658\" data-ts=\"1563803445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TBPH\" target=\"_blank\">TBPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479658-theravances-ampreloxetine-shows-positive-effect-in-mid-stage-noh-study-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Theravance&#39;s ampreloxetine shows positive effect in mid-stage nOH study; shares up 2%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17577938-theravance-biopharma-reports-new-data-phase-2-study-ampreloxetine-tdminus-9855-oral\" target=\"_blank\">New data</a> from a Phase 2 clinical trial evaluating Theravance Biopharma's (<a href='https://seekingalpha.com/symbol/TBPH' title='Theravance Biopharma, Inc.'>TBPH</a> <font color=\"green\">+1.9%</font>) ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) showed a treatment benefit. The results were presented at the European Neurology Congress in London.</li><li>Patients receiving amprelozetine experienced improvement in their overall nOH symptoms following four weeks of treatment that were sustained until the completion of 20 weeks of therapy. When therapy was discontinued, patients returned to their baseline pre-treatment levels.</li><li><a href=\"https://www.multiplesystematrophy.org/about-msa/neurogenic-orthostatic-hypotension/\" target=\"_blank\">Neurogenic orthostatic hypotension</a> is a disorder in which the autonomic system loses the ability to regulate blood pressure when a person stands up or changes positions quickly which results in a sudden and dangerous drop in blood pressure.</li><li>Ampreloxetine is a once-daily oral <a href=\"https://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20044970\" target=\"_blank\">norepinephrine reuptake inhibitor. </a></li></ul><div class=\"tiny-share-widget\" data-id=\"3479658\" data-linked=\"Theravance&#39;s ampreloxetine shows positive effect in mid-stage nOH study; shares up 2%\" data-tweet=\"$TBPH - Theravance&#39;s ampreloxetine shows positive effect in mid-stage nOH study; shares up 2% https://seekingalpha.com/news/3479658-theravances-ampreloxetine-shows-positive-effect-in-mid-stage-noh-study-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3479658-theravances-ampreloxetine-shows-positive-effect-in-mid-stage-noh-study-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479647\" data-ts=\"1563802684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLED\" target=\"_blank\">OLED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479647-oledminus-1_7-roth-steps-to-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OLED -1.7% as Roth steps to Neutral</a></h4><ul><li>Roth cuts Universal Display (NASDAQ:<a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a>) from Buy to Neutral and maintains the $194 price target.</li><li>The firm cites valuation with shares up about 160% from a January low, which means most of the potential upsides are priced in the stock.</li><li>Roth says the mobile market continues to represent a longer-term growth opportunity.</li><li>OLED shares are <font color=\"red\">down 1.7%</font> to $202.46.</li><li>Universal Display has a Neutral <a href=\"https://seekingalpha.com/symbol/OLED/ratings/quant-ratings\" target=\"_blank\">Quant rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479647\" data-linked=\"OLED -1.7% as Roth steps to Neutral\" data-tweet=\"$OLED - OLED -1.7% as Roth steps to Neutral https://seekingalpha.com/news/3479647-oledminus-1_7-roth-steps-to-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3479647-oledminus-1_7-roth-steps-to-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479639\" data-ts=\"1563802151\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479639-new-mediaplus-5-citi-boosts-to-buy-on-gannett-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Media +5% as Citi boosts to Buy on Gannett talks</a></h4><ul>   <li>New Media Investment Group (NYSE:<a href='https://seekingalpha.com/symbol/NEWM' title='New Media Investment Group Inc.'>NEWM</a>) is <font color=\"green\">up 5%</font> premarket alongside an upgrade to Buy at Citi.</li>    <li>The recent mover for the stock is news that the company's GateHouse Media is in <a href=\"https://seekingalpha.com/news/3479061-gannett-plus-10-percent-new-report-gatehouse-talks\" target=\"_blank\">advanced talks to combine</a> with Gannett (NYSE:<a href='https://seekingalpha.com/symbol/GCI' title='Gannett Co., Inc.'>GCI</a>) in a major newspaper merger.</li>    <li>There's a \"very high\" chance of success for that deal, which would come 50/50 in cash/stock, says analyst Jason Bazinet.</li>    <li>He's raised his price target to $14 from $10, implying 43% upside.</li>    <li>While <a href=\"https://seekingalpha.com/symbol/NEWM/ratings/sell-side-ratings\" target=\"_blank\">sell-side analysts rate NEWM a Buy</a>, it has a <a href=\"https://seekingalpha.com/symbol/NEWM/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Very Bearish</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479639\" data-linked=\"New Media +5% as Citi boosts to Buy on Gannett talks\" data-tweet=\"$NEWM $GCI - New Media +5% as Citi boosts to Buy on Gannett talks https://seekingalpha.com/news/3479639-new-mediaplus-5-citi-boosts-to-buy-on-gannett-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3479639-new-mediaplus-5-citi-boosts-to-buy-on-gannett-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479637\" data-ts=\"1563801941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAX\" target=\"_blank\">BAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479637-fda-oks-baxters-iv-insulin-myxredlin-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Baxter&#39;s IV insulin Myxredlin; shares up 1% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17578162-baxter-announces-u-s-fda-approval-myxredlin-first-ready-use-insulin-iv-infusion\" target=\"_blank\">approves </a>Baxter International's (NYSE:<a href='https://seekingalpha.com/symbol/BAX' title='Baxter International Inc.'>BAX</a>) Myxredlin (Insulin Human in 0.9% Sodium Chloride Injection), a ready-to-use short-acting insulin for intravenous &#40;IV&#41; infusion in hospital and acute care settings.</li><li>Shares are up <font color=\"green\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479637\" data-linked=\"FDA OKs Baxter&#39;s IV insulin Myxredlin; shares up 1% premarket\" data-tweet=\"$BAX - FDA OKs Baxter&#39;s IV insulin Myxredlin; shares up 1% premarket https://seekingalpha.com/news/3479637-fda-oks-baxters-iv-insulin-myxredlin-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3479637-fda-oks-baxters-iv-insulin-myxredlin-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479631\" data-ts=\"1563801498\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTAI\" target=\"_blank\">BTAI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479631-bioxcel-up-8-premarket-on-positive-early-stage-bxcl501-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioXcel up 8% premarket on positive early-stage BXCL501 data</a></h4><ul><li>Thinly traded micro cap BioXcel Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BTAI' title='BioXcel Therapeutics, Inc.'>BTAI</a>) is up <font color=\"green\">8% </font>premarket on average volume in response to <a href=\"https://seekingalpha.com/pr/17577660-bioxcel-therapeutics-announces-bxcl501-met-primary-endpoint-phase-1b-placebo-controlled-trial\" target=\"_blank\">positive data</a> from a Phase 1b clinical trial evaluating multiple doses of Fast Track-tagged BXCL501 for the acute treatment of agitation in 135 schizophrenia patients.</li><li>The three doses tested, 80 mcg, 120 mcg and 180 mcg, showed rapid calming without excessive sedation at hour two and earlier in a dose-dependent manner. The treatment effects for all three were statistically significant compared to placebo.</li><li>On the safety front, the most common treatment-related adverse events were drowsiness and dry mouth.</li><li>A pivotal Phase 3 study is next up pending a meeting with the FDA to clarify the design and protocol.</li><li>BXCL501 is a sublingual thin film formulation of the sedative dexmedetomidine, the active ingredient in Pfizer's Precedex.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479631\" data-linked=\"BioXcel up 8% premarket on positive early-stage BXCL501 data\" data-tweet=\"$BTAI - BioXcel up 8% premarket on positive early-stage BXCL501 data https://seekingalpha.com/news/3479631-bioxcel-up-8-premarket-on-positive-early-stage-bxcl501-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3479631-bioxcel-up-8-premarket-on-positive-early-stage-bxcl501-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479625\" data-ts=\"1563801188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479625-ntec-pets-lii-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NTEC, PETS, LII among premarket losers</a></h4><ul><li>Intec Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/NTEC' title='Intec Pharma Ltd.'>NTEC</a>) <font color=\"red\">-82%</font> after Accordion Pill <a href=\"https://seekingalpha.com/news/3479569-intec-pharmas-accordion-pill-flunks-late-stage-parkinsons-study-shares-78-percent-premarket\" target=\"_blank\">flunks</a> late-stage Parkinson's study.</li><li>Neuralstem (NASDAQ:<a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a>) <font color=\"red\">-24%</font> after <a href=\"https://seekingalpha.com/news/3479540-neuralstem-files-equity-offering-shares-19-percent-premarket\" target=\"_blank\">filing</a> for equity offering.</li><li>Midatech Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/MTP' title='Midatech Pharma Plc'>MTP</a>) <font color=\"red\">-11%</font>.</li><li>Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) <font color=\"red\">-7%</font>.</li><li>Vislink Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/VISL' title='Vislink Technologies, Inc.'>VISL</a>) <font color=\"red\">-6%</font>.</li><li>PaySign (NASDAQ:<a href='https://seekingalpha.com/symbol/PAYS' title='PaySign, Inc.'>PAYS</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3479567-btig-cuts-paysign-sell-stretched-valuation\" target=\"_blank\">analyst</a> downgrade.</li><li>PetMed Express (NASDAQ:<a href='https://seekingalpha.com/symbol/PETS' title='PetMed Express, Inc.'>PETS</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3479579-petmed-express-eps-misses-0_16-misses-revenue\" target=\"_blank\">Q1 results</a>.</li><li>Lennox International (NYSE:<a href='https://seekingalpha.com/symbol/LII' title='Lennox International Inc.'>LII</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3479557-lennox-eps-misses-0_38-misses-revenue\" target=\"_blank\">Q2 results</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479625\" data-linked=\"NTEC, PETS, LII among premarket losers\" data-tweet=\"$NTEC $SNCA $MTP - NTEC, PETS, LII among premarket losers https://seekingalpha.com/news/3479625-ntec-pets-lii-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3479625-ntec-pets-lii-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479624\" data-ts=\"1563801108\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479624-dva-amrx-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DVA, AMRX among premarket gainers</a></h4><ul><li>Peak Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/SKIS' title='Peak Resorts, Inc.'>SKIS</a>) <font color=\"green\">+113%</font> on being <a href=\"https://seekingalpha.com/news/3479574-peak-resorts-plus-112-percent-coming-trading-halt\" target=\"_blank\">acquired</a> by Vail Resorts.</li><li>Condor Hospitality Trust (NYSEMKT:<a href='https://seekingalpha.com/symbol/CDOR' title='Condor Hospitality Trust, Inc.'>CDOR</a>) <font color=\"green\">+33%</font> on <a href=\"https://seekingalpha.com/news/3479546-condor-hospitality-bought-318m\" target=\"_blank\">being acquired</a> by NexPoint Hospitality Trust.</li><li>BioXcel Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BTAI' title='BioXcel Therapeutics, Inc.'>BTAI</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/pr/17577660-bioxcel-therapeutics-announces-bxcl501-met-primary-endpoint-phase-1b-placebo-controlled-trial\" target=\"_blank\">positive top-line results</a> from the adaptive Phase 1b, randomized, double-blind, placebo-controlled, multi-center, U.S. trial, evaluating multiple doses of BXCL501 for acute treatment of agitation in 135 patients with schizophrenia.</li><li>Xenetic Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/pr/17577841-xenetic-biosciences-inc-closes-15_0-million-underwritten-public-offering-completes\" target=\"_blank\">closing $15M underwritten public offering</a> and completes acquisition of innovative CAR T technology platform.</li><li>DaVita (NYSE:<a href='https://seekingalpha.com/symbol/DVA' title='DaVita Inc.'>DVA</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/news/3479538-davita-5-percent-premarket-guidance-boost\" target=\"_blank\">guidance boost</a>.</li><li>Amneal Pharmaceuticals (NYSE:<a href='https://seekingalpha.com/symbol/AMRX' title='Amneal Pharmaceuticals, Inc.'>AMRX</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/news/3479571-amneal-launches-generic-lyrica-u-s-shares-6-percent-premarket\" target=\"_blank\">launching</a> generic Lyrica in U.S.</li><li>Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) <font color=\"green\">+5%</font> on <a href=\"https://seekingalpha.com/pr/17577937-biocept-announces-laboratory-services-provider-agreement-beaconlbs\" target=\"_blank\">announcing</a> laboratory services provider agreement with BeaconLBS.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479624\" data-linked=\"DVA, AMRX among premarket gainers\" data-tweet=\"$SKIS $CDOR $BTAI - DVA, AMRX among premarket gainers https://seekingalpha.com/news/3479624-dva-amrx-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3479624-dva-amrx-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479616\" data-ts=\"1563800461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHN\" target=\"_blank\">ACHN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479616-achillion-up-3-premarket-on-positive-achminus-5228-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achillion up 3% premarket on positive ACH-5228 data</a></h4><ul> <li>Achillion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>) <a href=\"https://seekingalpha.com/pr/17577766-achillion-s-achminus-5228-achieves-positive-results-phase-1-multiple-ascending-dose-study\" target=\"_blank\">announces</a> results from their Phase 1 multiple ascending dose study with ACH-5228 outside U.S.</li>     <li>43 healthy volunteers were enrolled in the study. Subjects received oral doses ranging from 40 mg to 200 mg twice a day &#40;BID&#41; for 14 days. </li><li>The results demonstrated that ACH-5228, when dosed 120 mg BID or higher, achieved near complete and sustained Alternative Pathway inhibition with a mean value of &gt;95% at steady state concentrations.</li>  <li>ACH-5228 was well tolerated over the dose ranges, which include the doses expected to be evaluated in Phase 2 trials.</li><li>The Company expects to submit an IND application in Q4 2019.</li><li>Shares are up <font color=\"green\">3%</font> premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3479616\" data-linked=\"Achillion up 3% premarket on positive ACH-5228 data\" data-tweet=\"$ACHN - Achillion up 3% premarket on positive ACH-5228 data https://seekingalpha.com/news/3479616-achillion-up-3-premarket-on-positive-achminus-5228-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3479616-achillion-up-3-premarket-on-positive-achminus-5228-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479614\" data-ts=\"1563800401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LII\" target=\"_blank\">LII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479614-lennox-down-6-on-earnings-miss-and-reduced-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lennox down 6% on earnings miss and reduced outlook</a></h4><ul><li>Lennox (NYSE:<a href='https://seekingalpha.com/symbol/LII' title='Lennox International Inc.'>LII</a>) reports adjusted revenue was down 1% in <a href=\"https://seekingalpha.com/pr/17577800-lennox-international-reports-second-quarter-results\" target=\"_blank\">Q2</a>.</li><li>The tornado had a negative 3% impact on revenue growth in the quarter.</li><li>Residential Heating &amp; Cooling segment revenue decreased 4% to $689.1M.</li><li>Commercial Heating &amp; Cooling segment revenue rose 4% to $261.3M.</li><li>Refrigeration segment revenue grew 2% to $148.7M.</li><li>Adjusted gross margin rate fell 140 bps to 30.2%.</li><li>Total segment margin -10 bps to 18.4%.</li><li><b>FY2019 Guidance</b>: Adjusted revenue: +2% to +5%; Adjusted EPS: $11.30 to $11.90; GAAP EPS: $11.91 to $12.51; Tax rate: 22% to 23%; Capex: ~$155M; Free cash flow: ~$390M; Stock repurchase: $400M.</li><li>Chairman and CEO Todd Bluedorn said, \"For 2019 overall, we now expect $99M of negative tornado impact to Residential revenue, up from $70M previously; a negative $54M impact to segment profit, up from $40M previously; and insurance recovery for lost profits of $94M, up from $80M previously. The resulting $40M of net benefit to Residential segment profit in 2019 is unchanged.</li><li>LII <font color=\"red\">-5.7%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3479557-lennox-eps-misses-0_38-misses-revenue\" target=\"_blank\">Lennox EPS misses by $0.38, misses on revenue</a> (July 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3479614\" data-linked=\"Lennox down 6% on earnings miss and reduced outlook\" data-tweet=\"$LII - Lennox down 6% on earnings miss and reduced outlook https://seekingalpha.com/news/3479614-lennox-down-6-on-earnings-miss-and-reduced-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3479614-lennox-down-6-on-earnings-miss-and-reduced-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479613\" data-ts=\"1563799913\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479613-fda-oks-inclusion-of-new-survival-data-in-labeling-of-astrazenecas-imfinzi-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs inclusion of new survival data in labeling of AstraZeneca&#39;s Imfinzi; shares up 1% premarket</a></h4><ul><li>AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a>) perks up <font color=\"green\">1%</font> premarket on light volume following its <a href=\"https://seekingalpha.com/pr/17577870-imfinzi-durvalumab-us-label-updated-overall-survival-data-unresectable-stage-iii-non-small\" target=\"_blank\">announcement </a>that the FDA has signed off on including overall survival &#40;OS&#41; data from the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02125461?titles=pacific&amp;lead=astrazeneca&amp;phase=2&amp;rank=2\" target=\"_blank\">PACIFIC</a> study in the package insert of IMFINZI (durvalumab) for patients with unresectable Stage III non-small cell lung cancer &#40;NSCLC&#41; who have not progressed following concurrent platinum-based chemo and radiation therapy.</li><li>The data showed an OS benefit compared to placebo with a 32% reduction in the risk of death.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479613\" data-linked=\"FDA OKs inclusion of new survival data in labeling of AstraZeneca&#39;s Imfinzi; shares up 1% premarket\" data-tweet=\"$AZN - FDA OKs inclusion of new survival data in labeling of AstraZeneca&#39;s Imfinzi; shares up 1% premarket https://seekingalpha.com/news/3479613-fda-oks-inclusion-of-new-survival-data-in-labeling-of-astrazenecas-imfinzi-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3479613-fda-oks-inclusion-of-new-survival-data-in-labeling-of-astrazenecas-imfinzi-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479602\" data-ts=\"1563798693\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSY\" target=\"_blank\">HSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479602-ubs-warms-up-to-hershey\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS warms up to Hershey</a></h4><ul> <li>UBS says its thesis on Hershey (NYSE:<a href='https://seekingalpha.com/symbol/HSY' title='The Hershey Company'>HSY</a>) has shifted away from a bearish one.</li> <li>\"First, consolidation in U.S. confection has driven better category stewardship as privately owned competitors Ferrero and Mars have elevated the chocolate industry\u2019s profit pool by enhancing ingredients and packaging rather than competing on promotions. Second, US confection pricing power is stronger than we initially assessed. Last week Mars announced ~10% price increases for front-of-store confection,\" reads the UBS note to clients.</li> <li>The firm moves to a Neutral rating on Hershey and hikes its price target to $145 from $100 vs. the <a href=\"https://seekingalpha.com/symbol/HSY/ratings/sell-side-ratings?s=hsy\" target=\"_blank\">sell-side average PT</a> of $131.31.</li> <li>Shares of Hershey are <font color=\"green\">up 0.48%</font> premarket to $145.88.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479602\" data-linked=\"UBS warms up to Hershey\" data-tweet=\"$HSY - UBS warms up to Hershey https://seekingalpha.com/news/3479602-ubs-warms-up-to-hershey?source=tweet\" data-url=\"https://seekingalpha.com/news/3479602-ubs-warms-up-to-hershey\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479598\" data-ts=\"1563798289\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRRX\" target=\"_blank\">DRRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479598-durect-up-39-premarket-on-gilead-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Durect up 39% premarket on Gilead deal</a></h4><ul><li>DURECT (NASDAQ:<a href='https://seekingalpha.com/symbol/DRRX' title='DURECT Corporation'>DRRX</a>) is up <font color=\"green\">39%</font> premarket on light volume in reaction to its <a href=\"https://seekingalpha.com/pr/17577886-durect-gilead-enter-license-agreement-long-acting-injectable-hiv-investigational-product\" target=\"_blank\">out-license agreement</a> with Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) granting the latter exclusive global rights to develop and commercialize a long-acting HIV product utilizing its SABER technology.</li><li>GILD will also receive exclusive access the SABER platform for HIV and HBV and an exclusive option to in-license additional SABER-based products directed to HIV and HBV.</li><li>Under the terms of the deal, GILD will pay DRRX $25M upfront, up to $75M in development and regulatory milestones, up to $70M in sales-based milestones and tiered royalties on net sales. If GILD exercises its option for additional SABER products, it will pay an additional $150M upfront per product plus milestones and tiered royalties on net sales.</li><li>The companies will collaborate on specific development activities. GILD will control and fund the development programs.</li><li>SABER (Sucrose acetate isobutyrate extended-release) is a technology that enables sustained release of long-acting injectables.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479598\" data-linked=\"Durect up 39% premarket on Gilead deal\" data-tweet=\"$DRRX $GILD - Durect up 39% premarket on Gilead deal https://seekingalpha.com/news/3479598-durect-up-39-premarket-on-gilead-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3479598-durect-up-39-premarket-on-gilead-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479597\" data-ts=\"1563798227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRNX\" target=\"_blank\">TRNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479597-taronis-tech-inks-potential-165m-deal-to-sell-up-to-30-gasification-units\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Taronis Tech inks potential $165M deal to sell up to 30 gasification units</a></h4><ul><li>Taronis Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/TRNX' title='Taronis Technologies, Inc.'>TRNX</a>) <font color=\"green\">+83.5%</font> pre-market after announcing a <a href=\"https://seekingalpha.com/pr/17577701-taronis-executes-165-million-contract\" target=\"_blank\">binding purchase contract</a> with a Turkish gas consortium for as many as 30 gasification units valued at up to $165M.</li><li>The deal terms include the purchase of 15 units over 18 months with an option to buy an additional 15 units, and a perpetual 3% royalty on all gas produced; each gasification unit carries an upfront purchase price of $3.75M and will include a 10-year maintenance contract for an additional $1.75M/unit.</li><li>\"This has the potential to be a financially transformational opportunity for our company,\" says Taronis CEO Scott Mahoney.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479597\" data-linked=\"Taronis Tech inks potential $165M deal to sell up to 30 gasification units\" data-tweet=\"$TRNX - Taronis Tech inks potential $165M deal to sell up to 30 gasification units https://seekingalpha.com/news/3479597-taronis-tech-inks-potential-165m-deal-to-sell-up-to-30-gasification-units?source=tweet\" data-url=\"https://seekingalpha.com/news/3479597-taronis-tech-inks-potential-165m-deal-to-sell-up-to-30-gasification-units\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479595\" data-ts=\"1563798027\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PETS\" target=\"_blank\">PETS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479595-petmed-express-down-11-premarket-on-q1-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PetMed Express down 11% premarket on Q1 miss</a></h4><ul><li>PetMed Express (<a href='https://seekingalpha.com/symbol/PETS' title='PetMed Express, Inc.'>PETS</a>) <a href=\"https://seekingalpha.com/pr/17577905-petmed-express-d-b-1minus-800-petmeds-announces-first-fiscal-quarter-financial-results\" target=\"_blank\">Q1 results</a>: Revenues: $80M (-8.5%).</li><li>Net Income: $5.3M (-57.9%); EPS: $0.26 (-58.1%); CF Ops: $0.04M (-99.8%).</li><li>Shares are down <font color=\"red\">11%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3479579-petmed-express-eps-misses-0_16-misses-revenue\" target=\"_blank\">PetMed Express EPS misses by $0.16, misses on revenue</a> (July 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3479595\" data-linked=\"PetMed Express down 11% premarket on Q1 miss\" data-tweet=\"$PETS - PetMed Express down 11% premarket on Q1 miss https://seekingalpha.com/news/3479595-petmed-express-down-11-premarket-on-q1-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3479595-petmed-express-down-11-premarket-on-q1-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479587\" data-ts=\"1563797531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYCC\" target=\"_blank\">CYCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479587-dosing-underway-in-study-of-cyclacels-sapacitabine-in-certain-blood-cancers-shares-up-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dosing underway in study of Cyclacel&#39;s sapacitabine in certain blood cancers; shares up 8% premarket</a></h4><ul><li>Nano cap Cyclacel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a>) is up <font color=\"green\">8%</font> premarket on light volume following its <a href=\"https://seekingalpha.com/pr/17577740-cyclacel-pharmaceuticals-announces-first-patient-treated-phase-1-2-study-sapacitabine\" target=\"_blank\">announcement </a>that the first patient has been dosed in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT01211457?term=Cyclacel&amp;rank=9\" target=\"_blank\">Phase 1/2 clinical trial</a> evaluating oral sapacitabine, a nucleoside analogue prodrug, combined with AbbVie's oral <a href=\"https://www.venclexta.com/\" target=\"_blank\">Venclexta </a>(venetoclax), a BCL-2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia &#40;AML&#41; or myelodysplastic syndromes &#40;MDS&#41;.</li><li>The primary endpoint of the 40-subject study is the response rate at year two.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479587\" data-linked=\"Dosing underway in study of Cyclacel&#39;s sapacitabine in certain blood cancers; shares up 8% premarket\" data-tweet=\"$CYCC - Dosing underway in study of Cyclacel&#39;s sapacitabine in certain blood cancers; shares up 8% premarket https://seekingalpha.com/news/3479587-dosing-underway-in-study-of-cyclacels-sapacitabine-in-certain-blood-cancers-shares-up-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3479587-dosing-underway-in-study-of-cyclacels-sapacitabine-in-certain-blood-cancers-shares-up-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479580\" data-ts=\"1563797001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWL\" target=\"_blank\">NWL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479580-legal-victory-for-newell-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Legal victory for Newell Brands</a></h4><ul> <li>Newell Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/NWL' title='Newell Brands Inc.'>NWL</a>) saw a Delaware judge <a href=\"https://www.reuters.com/article/us-jarden-newell-brands-hedge-funds/judge-rules-against-hedge-funds-that-challenged-2016-jarden-deal-idUSKCN1UE2KC\" target=\"_blank\">rule</a> against hedge funds looking to get more cash out of the acquisition of Jarden Corp. through an appraisal process.</li> <li>The judge determined that the fair value of Jarden stock was $48.31 when it was acquired by Newell, well below the $71.35 sought by funds affiliated with Fir Tree Partners and Verition Fund Management.</li> <li>The funds can file an appeal.</li> <li>Shares of Newell are <font color=\"green\">up 0.70%</font> premarket to $14.43.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3479580\" data-linked=\"Legal victory for Newell Brands\" data-tweet=\"$NWL - Legal victory for Newell Brands https://seekingalpha.com/news/3479580-legal-victory-for-newell-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3479580-legal-victory-for-newell-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3479576\" data-ts=\"1563796809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BP\" target=\"_blank\">BP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3479576-bp-bunge-to-form-brazil-bioenergy-jv\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BP, Bunge to form Brazil bioenergy JV</a></h4><ul><li>Bunge (NYSE:<a href='https://seekingalpha.com/symbol/BG' title='Bunge Limited'>BG</a>) says it will <a href=\"https://seekingalpha.com/pr/17577686-bunge-bp-create-leading-bioenergy-company\" target=\"_blank\">form a 50-50 joint venture</a> with <a href='https://seekingalpha.com/symbol/BP' title='BP p.l.c.'>BP</a> to create the <a href=\"https://www.marketwatch.com/story/bunge-bp-to-form-brazil-bioenergy-jv-2019-07-22\" target=\"_blank\">second largest bioenergy company in Brazil</a> in terms of effective crushing capacity.</li><li>BP Bunge Bioenergia will operate on a stand-alone basis and operate 11 mills in Brazil, and with 32M metric tons of combined annual crushing capacity, it will have the flexibility to produce a mix of ethanol and sugar.</li><li>Bunge says it will receive cash proceeds of $775M in the deal, including $700M in respect of non-recourse Bunge debt to be assumed by the JV and $75M from BP.</li><li>BG <font color=\"green\">+2.5%</font>, BP <font color=\"green\">+0.3%</font> pre-market.</li></ul><div class=\"tiny-share-widget\" data-id=\"3479576\" data-linked=\"BP, Bunge to form Brazil bioenergy JV\" data-tweet=\"$BP $BG $BG - BP, Bunge to form Brazil bioenergy JV https://seekingalpha.com/news/3479576-bp-bunge-to-form-brazil-bioenergy-jv?source=tweet\" data-url=\"https://seekingalpha.com/news/3479576-bp-bunge-to-form-brazil-bioenergy-jv\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}